Natalie SERKOVA, Ph.D.
Current Title
Associate Professor
INSTITUTION AND LOCATION
DEGREE
Department
Anesthesiology
Pharmacology (secondary)
Radiology (secondary)
YEAR(s)
FIELD OF STUDY
Joseph Fourier University, Grenoble, France
University of Kiev, Ukraine
B.S.
M.S.
1991
1992
University of Bremen, Germany
Ph.D.
1996
Postdoctoral
1997-1999
University of California, San Francisco
Physics
Biophysics/ Medical
Physics
Biochemistry/ Radiol
Sciences
“magna cum laude”
Clinical
Pharmacokinetics
Denver, March 3rd, 2014
Specialty; Subspecialty
Magnetic Resonance Spectroscopy/ Magnetic Resonance Imaging
Animal Imaging (MRI, PET, CT)
Molecular Imaging
Metabolomics
Targeted Cancer Treatment
Directing Imaging Core Facility
Employment
1998-1999
Head of animal MRI laboratory, Departments
Biopharmaceutical Sciences, University of California, San Francisco
of
Pharmaceutical
Chemistry
and
1999-2000
Visiting Assistant Professor, Department of Biopharmaceutical Sciences, University of
California, San Francisco
1999-2002
Assistant Professor, NMR Metabolomics Division, Institute of Chemistry and Biology, University
of Bremen, Germany
2002-present Assistant Professor (tenure track), Department of Anesthesiology, University of Colorado Health
Sciences Center, Denver, Colorado
2003-present Assistant Professor (secondary appointment), Department of Pharmacology, University of
Colorado Health Sciences Center, Denver, Colorado
2004-present Director, Biomedical MRS Core, University of Colorado Comprehensive Cancer Center, Denver,
Colorado
2005-present Director, Animal Imaging Shared Resources (AISR), University of Colorado Comprehensive
Cancer Center, Denver, Colorado
2005-present Assistant Professor (secondary appointment), Department of Radiology, University of Colorado
Health Sciences Center, Denver, Colorado
July 2006
Promotion to an Associate Professorship Rank
2008-present Director, Translational Imaging and Metabolomics Core, Colorado Clinical Translational Science
Institute (CCTSI)
2009-present Director, Animal Imaging Center, Colorado Translational Research Imaging Center (C-TRIC)
Awards and Honors
1993 Postgraduate Scholarship, German Research Foundation (DFG), Bonn, Germany
1997
Postdoctoral Scholarship, Alexander von Humboldt-Foundation, Bonn, Germany
1998 Young Investigator and Travel Award of the International Society of Magnetic Resonance in Biological
Systems
1999
Emmy-Noether Award Grant of the German Research Foundation (DFG), Bonn
2004 New Strategic Research Initiative Award by the Academic Enrichment Fund (AEF) of the School of
Medicine, University of Colorado Health Sciences Center
2004
External Reviewer for Canadian National Institutes of Health Research (CIHR/ IRSC)
2005
NIH Reviewer for the National Institutes of Health, Shared Instrumentation Grant Study Section
2005
University of Colorado Cancer Center Start-Up Fund Gift
2006 Harry Vars Award for the top manuscript at the American Society of Parenteral and Enteral Nutrition
Meeting
2006
Generations Cancer Foundation Award
2006- Reviewer for The Wellcome Trust (Great Britain)
2007
Reviewer for South African Medical Research Council (MRC)
2008
Reviewer for NASA and US Department of Energy
2008- Reviewer for ACS and UCCC Seed Grants (UCD Anschutz)
2009- Reviewer for CCTSI Grants (UCD Anschutz)
2009- NCI Reviewer, Technology in Cell Biology Study Section
2009- Member of the Student Cancer Research Fellowship Review Committee (UCD Anschutz)
2009- NCI Reviewer, the Cancer Biomarker Study Section (ZRG1 BDA-A(58)).
2009- NIBIB Reviewer, the Challenge Grant Panel #23 (ZRG1 SBIB-V(58)).
2009- NCI Reviewer, the Challenge Grant Panel #10 (ZRG1 BDA-A(58)).
2009- International Society of Magnetic Resonance in Medicine (ISMRM) Award for the 2009 Best Molecular
Imaging Project (2nd place)
2009- NCI Reviewer, Integrative Cancer Biology Program/ System Biology (ZCA1 SRLB-C (J1)R)
2009- NIBIB Reviewer, Bioengineering Research Partnerships and Imaging (ZRG1 SBIB-V (50))
2010- External Reviewer for Cancer Research UK/ Biomarkers and Imaging Development Committee
2010- Reviewer for Colorado Boettcher Foundation Webb-Waring Grants
2010- NIH Reviewer, Recovery Act Limited Competition: Director’s Opportunity 5 Themes Oral,
Musculoskeletal and Imaging (2010/08 ZRG1 MOSS-G (55)R).
2011- External Reviewer for the ANR/ French National Research Agency (ad-hoc)
2011-2013 External Reviewer for the Netherlands Organization for Scientific Research (NWO, the Dutch
Research Council, ALW-IN/12-18) (ad-hoc)
2012- Member of the Onsite Panel Review for the U.S. Department of Energy Office of Science Graduate
Fellowship (DOE SCGF) Program
2012-2017 Reviewer for the California Breast Cancer Research Program, “Treatment and Detection” Review
Committee (ad-hoc)
2012- Special Emphasis NIH Panel Reviewer on “Technology Development for Metabolomics” (ZRG1 BST-p
(50))
2013- NIH Reviewer, SPIR Topic 320 “Standards for Metabolomics”
Projects Ongoing, Pending or Completed in the Last Five Years
Ongoing (recently funded):
2006:
NCI P30 (CA046934-25, Cancer Center Core Grant, PI: Theodorescu) Role: Director of Animal
Imaging Shared Resources (30%)
2008:
NCATS UL1TR001082, KL2TR001080, TL1TR001081 “Colorado Clinical Translational Sciences
Institute, CCTSI”, principal investigator: Dr. Ronald J. Sokol (TCH), role: Director of Translational
Imaging and Metabolomics Core (10%)
2011:
AMC Cancer Fund Pilot Grant “Metabolomics of Glioblastomas and Tumor Tissues in a Novel
Organotype Tumor Slice Culture Model: Stress Responses and the Dynamic Tumor
Metabolome”, principal investigator: M. Graner/ N. Serkova/ A. Waziri (n/a).
2011:
NIH 1R01 HD065534 “Efficacy of Flupirtine for Treatment of Neonatal Hypoxic-Ischemic
Encephalopathy”, principal investigator: Y. Raol. Role: Co-investigator (5%)
2012:
NIH 1R01 DE021788 “The Role of PI3K Pathway in Head and Neck Cancer Invasion and
Metastasis”, principal investigator: S.-L. Lu. Role: Co-investigator (5%)
2012:
NIH 1R25 GM103798 “University of Alabama Metabolomics Workshop: from Design to Decision”,
principal investigator: S. Barnes (UAB). Role: Co-investigator (honorarium)
Pending:
NIH R01 “A Novel MR/CT Contrast Agent for Prostate Cancer Imaging and Diagnosis” (#11035155)
PIs: P. Werahera/ S. Boyes
Role: Co-investigator
NIH R01 “Mechanisms of Immunosuppressant Drug Actions in Reducing Alcohol Consumption”
PI: T. Beresford
Role: Co-investigator
Completed:
2003:
NIH-Grant (RO1 HL071805-01) entitled “The Role of Statin Lactones in Statin Toxicity”, principal
investigator: Dr. U. Christians (Dept. Anesthesiology, UCHSC). Role: Co-investigator
2003:
NIH-Grant (RO1 DK065094-01) entitled “Effect of Immunosuppressants on Cell Metabolism”,
principal investigator: Dr. U. Christians (Dept. Anesthesiology, UCHSC). Role: Co-PI
2004:
DOD-Grant (PC041000) entitled “Magnetic Resonance Spectroscopy (MRS) of Prostatic Fluids
for Early Detection of Prostate Cancer”, principal investigator: Dr. E.D. Crawford (Dept. Radiation
Oncology), Role: Co-PI
NIH-Grant (S10 RR019316-01) entitled “In Vivo Spectroscopy/ Imaging System PharmaScan
47/16”, principal investigator: N. Serkova
2005:
2005:
NCI-Grant (1 R21 CA108624-01) entitled “Metabolic Signature of Imatinib Resistance”, principal
investigator: N. Serkova
2006:
Colorado Cancer Generation Fund Grant entitled “Building a Research Imaging Core at the
Anschutz Medical Center:, principal investigator: N. Serkova
2006:
FAER Mentores Training Grant entitled “Isoflurane-induced neurodegeneration: a function of
age”, principal investigator: Dr. L. Wise-Faberowski (Dept. Anesthesiology), Role: Mentor
2007:
SIRC-Grant (UCHSC, Dean Office of School of Medicine) entitled “Pre-Clinical Positron Emission
and Computed Tomography (PET/CT)”, principal investigator: N. Serkova
2007:
Eli Lilly and Company grant entitled “Magnetic Resonance Evaluations on Enzastaurin Treatment
in Colon Cancer Animal Models”, principal investigator: N. Serkova
2008:
NIH-Grant (R01 GM078312-01A2) entitled „Mechanism of Heat Shock Protein Induction by
Glutamine“, principal investigator: Dr. P. Wischmeyer (Dept. Anesthesiology), Role: Coinvestigator
2008:
NIH-Grant (R21 AA016294-01) entitled “Neuro-Immunophyllin Ligand Mechnism of Action in
Reducing Alcohol”, principal investigator: Dr. T. Beresford (Dept. Psychiatry), Role: Coinvestigator (5%)
2008:
The Jeannik M. Littlefield-AACR Grant entitled “Development of Rational Treatment Algorithms
for Colorectal Cancer”, principal investigator: Dr. SG Eckhardt (dev. Medical Oncology), Role: Coinvestigator (5%)
2009:
Facet Biotech Corporation grant entitled “Pre-Clinical Positron Emission Tomography Evaluations
on the Efficacy of PDL192, a Humanized IgG1 monoclonal antibody”, principal investigator: N.
Serkova (10%)
2009:
NHLBI RC1 HL100849 “Zipcode Based Nano-Imaging of Hypertensive Pulmonary Arteries”,
principal investigator: R. Tuder. Role: Co-investigator (5%)
Patents
US 2011/ 0286938 A1: “Non-Invasive Detection of Complement-Mediated Inflammation Using CR2-Targeted
Nanoparticles” (Nov 24, 2011, Inventors: Thurman, Serkova, Stoldt, Larsen).
US 2012/0064009 A1: “Methods for Leukemia Cell Detection” (March 15, 2012; Inventors: Gore, DeRyckere,
Macy, Serkova).
Teaching and Mentoring Experience
Graduate Faculty, Structural Biology and Biochemistry Graduate Program
Graduate Faculty, Pharmacology Graduate Program
Member of the Advisory Committee for the K12 Paul Calabrese Clinical Oncology Scholars Program (2012present).
Basic Pharmacology (40 hrs, University of Bremen, 1999);
Pharmacology I (40 hrs, University of Bremen, 2000);
Spectroscopic Methods in Biology and Medicine (80 hrs, University of Bremen, 2000); Pharmacology II (40 hrs,
University of Bremen, 2001);
Biomedical NMR (20 hrs, UCHSC, Anesthesiology Dept., 2002);
Magnetic Resonance in Biomedicine (20 hrs, UCHSC, Anesthesiology Dept., 2003);
Cancer: Experimental and Medical Aspects (2 hrs, PHSC7530, Spring Semester 2007);
Organizer for Anesthesiology Seed Grant Program (2008 –present);
Anschutz Campus Student Research Forum: Reviewer (2008 – present);
Onsite training on sample handling and extraction for NMR-based metabolomics for UCD and external
researchers (2004 – present, in average 3 weeks per year);
Onsite training on MR safety and principles (2005 – present, in average 2 weeks per year);
Onsite training on animal handling during imaging studies (2006 – present, in average 2 weeks per year);
Onsite training on imaging software for Core users (2008 – present, in average 2 weeks per year);
NCI Summer Scholarship Reviewer (2008 – present);
Cancer Center Summer Fellowship Lectures “The Imaging Approach” (2010 – present);
Educational Courses for the International Society of Magnetic Resonance in Medicine (ISMRM, 2011-present);
Drug Metabolism (3 hrs, Dental School Basic Science 6600, Fall Semester 2003-present );
Iron oxide nanoparticles for MR imaging and drug delivery (2 hrs, PHSC 7345 Nanotechnology and Drug
Delivery, Spring 2011-present);
Functional and Molecular Imaging on Small Animals (4 hrs, BIOE 5031 Technology for Bioengineers I, Spring
2011-present).
Doctoral Dissertations and Diplomas Completed under Mentorship/ PhD Thesis Committee
2001 Jelena Miljus: “The role of free radical formation in the metabolic effects of immunosuppressants in
brain cells” (Biochemistry B.S. Diploma, University of Bremen);
2002 Timo Dansauer: “MRS Assessment on metabolic effects of Gleevec in human chronic myelogenious
EM3 cells” (Biochemistry B.S. Diploma, University of Bremen);
2003 Sven Gottschalk: “Effects of macrolide immunosuppressants on mitochondrial metabolism:
Combination with cyclosporine” (Ph.D. Thesis, University of Bremen);
2003 Nora Anderson: “Time dependent effects of imatinib mesylate on human leukemia cells and primary
leukocytes” (M.D. Thesis, Medizinische Hochshule Hannover);
2010 Robert Anthony Hom: “Binding of the Cyp33 RRM domain to the MLL PHD3” (Ph.D. Thesis, BMS
Program, Dept Pharmacology, School of Medicine, UCD);
2010 Darin J. Brown: “NMR Methods to enhance spectral resolution and increase molecular weight” (Ph.D.
Thesis, BMS Program, Dept Pharmacology, School of Medicine, UCD);
2012 Daniel McShan: “Computational Bioalchemy: Optimal Search Algorithms for the Analysis and
Synthesis of Metabolic Systems” (Ph.D. Thesis, Computational Bioscience Program, Dept
Pharmacology, School of Medicine, UCD);
2012 Michael Rudolph: “Thyroid Hormone Responsive Protein Spot 14 Modulates Fatty Acid Synthase
Kinetics and Fatty Acid Products” (Ph.D. Thesis, Molecular Biology Program, Dept. Pathology, School
of Medicine, UCD).
Graduate and Under-Graduate Students under Mentorship
2003-2006
William Lapin, Research Student (John Washington University)
2004-2007
John Leslie Coatney, M.D. Student, School of Medicine (UCHSC)
2005-2006
Daniel C McShan, Bioinformatics (UCHSC)
2005-2006
Yu Zhang, Bioinformatics/ Pharmacology (UCHSC)
2006
Brian Henning, Research Student (Boston College)
2006-2008
2006-2009
2008
2008-2012
2009
2009
2010
2010
2011
2011
2011
2012
2012-2015
2012-2013
2013
2013
2013-2016
2014
Daniel Cromer, Research Student (CU Boulder)
Brian Larsen, Chemical Engineering (CU Boulder)
Brian Hamm, Medical Student (UCDHSC)
Michael Rudolph, PhD Student (UCD, MOLB Program)
Chris Haberkorn, Chemistry/ Biology (CSU, NCI Scholarship)
Matthew S. Burns, PhD Student (UCD, BSP Program)
Douglas Robinson, NCI Summer Student, Chemistry, CSU
Scott Bluth, MD FAER Summer Student, Univ of Texas, SOM
Lindsay Garcia, ASPET SURF Summer Scholarship, California State University
Daniel April, NCI Summer Student, Colorado State University
Max Geselkovich, UCD Downtown Premed Summer Student
Devin Ward, CTSA/ DSST Student
Justin Lee, MD Candidate, University of Colorado SOM, Research Track
Marina Stukova, Undergraduate Student, University of Colorado Denver Downtown
Brandon Hammond, MD FAER Student, University of Arizona
Jerry Choi, NCI Scholarship Undergraduate, Oberlin University
Julio Montejano, MD Candidate, University of Colorado SOM, Research Track
Samuel Day, MD Candidate (4 year)
Professional Research Personnel, Postdoctoral Fellows, Residents and Faculty under
Mentorship
2000-2002
Carsten Hainz, Ph.D.: MRS studies on toxicity of novel immunosuppressants
2002-2003
Lisa Frisch, M.S.: Metabolic effects of Gleevec on chronic myelogenious leukemia
2003-2004
Saskia Trump, Ph.D.: MRS based metabonomics on human melanoma biopsies
2003Jaimi L. Brown, B.S.: MRS based metabonomics on fatty livers
2004Douglas Kominsky, Ph.D.: Quantitative MRS based metabolomics
2004-2006
Bryan Bergman, M.D.: Intramuscular triglyceride turnover and insulin sensitivity (K-08 Award)
2004-2006
Warren Capell, M.D.: The role of lipoprotein lipase in myocyte fuel partitioning (K-08 Award)
2004-2006
S. Gail Eckhardt, M.D.: Metabolic Signature of Human Malignancies and Their Response to
the Treatment (K-24 Award)
2005-2006
Holly Tuttle, M.S.: Regional Metabolic Heterogeneity of Canine Spontaneous Tumors Using
1
H- and 31P-NMR. (Merck Merial Research project, Colorado State University).
2005-2006
Teresa Troiani, M.D.: DCE-MRI on Colon Xenografts (Astra Zeneca Scholarship)
2006-2008
Lisa Wise-Faberowski, M.D.: Isoflurane – induced neurodegeneration: a function of age
(FAER Mentors Training Grant)
2006Kendra M. Hasebroock, R.T.: Small Animal Imaging.
2007-2008
Jennifer Spratlin, M.D. (Oncology Fellow): Cancer Metabolomics
2007Andrea Merz, B.S.: Metabolic NMR sample proceeding and analysis.
2007-2009
Erica L. Bradshaw-Perce, Ph.D.: Pharmacokinetic modeling in DCE-MRI and FDG-PET in
animal cancer models (UCD T32 Developmental Therapeutic Training Grant).
2008-2010
Deborah DeRyckere, Ph.D.: Functional Imaging in Transgenic Leukemic Mice.
2008-2011
Misty D. Rowe, Ph.D.: Gadolinium-Based Nanoparticles for Molecular Imaging and Drug
Delivery.
2009-2010
Radhika Srinivasan, Ph.D. (UCSF, Radiology): Extraction Protocol Development for NMR
2009-2010
Tessa Little, Ph.D. (University of Pretoria, Biochemistry, South Africa): NMR-Based
Metabolomics.
2009-2010
Liping Huang, M.D. (Shengjing Hospital of China Medical University): Postdoctoral training
in Pre-Clinical Imaging in Oncology
2010-2012
Curtis J. Henry, Ph.D.: Declining Lymphoid Progenitor Fitness Promotes Aging Associated
Leukemogenesis (UCD T32 Aging Training Grant).
2012-2017
Curtis J. Henry, Ph.D.: Metabolic Consequences of Leukemogenesis (K01 CA160798-01A1
NCI Mentored Career Development Award to Promote Diversity)
2012-2014
Daniel Golovko, M.D.: Contrast-Enhanced T2-MRI in Acute Kidney Injury: Inflammation
Imaging with SPIO Nanoparticles.
Memberships (* elected/ peer-reviewed):
2002
International Society of Magnetic Resonance in Medicine (ISMRM)*
2003
University of Colorado Cancer Center (UCCC)*
2004-2008 American Society of Transplant Surgeons (ASTS)*
2006
Society of Molecular Imaging (SMI)*
2008
Colorado Clinical and Translational Sciences Institute (CCTSI)
2010
American Association for Cancer Research (AACR)*
2011-2012 American Society for Pharmacology and Experimental Therapeutics (Aspet)
2012
Radiological Society of North America (RSNA)*
2012
American Association for Clinical Chemistry (AACC)
Reviewer for:
African Journal of Pharmacy and Pharmacological Research
American Journal on Neuroradiology
American Journal of Physiology; Gastrointestinal and Liver Physiology
American Journal of Physiology; Lung Cellular and Molecular Physiology
American Journal of Respiratory and Critical Care Medicine
American Journal of Transplantation
Analytical Biochemistry
Analytical Chemistry
Anesthesiology
Bioanalysis
Biochemical Pharmacology
Bioconjugate Chemistry
BioMed Central (various)
Brain Research
British Journal of Pharmacology
Cancer Research
Cell Biology and Toxicology
Cellular and Molecular Life Sciences
Chemical Research in Toxicology
Clinical Cancer Research
Clinical Chimica Acta
Computed Methods and Programs in Biomedicine
Current Cancer Drug Targets
Digestion
Drugs
Ecotoxicology and Environmental Safety
Environmental Science and Technology
European Journal of Pharmaceutical Sciences
Expert Review of Molecular Diagnostics/ Other Series
Free Radicals in Biology and Medicine
Gastroenterology
Hepatology
International Brazilian Journal of Urology
International Journal of Cancer
International Journal of Molecular Sciences
International Journal of Radiation Biology
Journal of Agricultural and Food Chemistry
Journal of the American Society of Nephrology
Journal of Biomedicine and Biotechnology
Journal of Cellular and Molecular Medicine
Journal of Cerebral Blood Flow and Metabolism
Journal of Clinical Anesthesiology
Journal of Clinical Oncology
Journal of Lipid Research
Journal of Magnetic Resonance Imaging
Journal of Neurology
Journal of Proteome Research
Leukemia
Leukemia and Lymphoma
Metabolism
Metabolites
Metabolomics
Mini-Reviews in Medicinal Chemistry
Molecular Cancer Therapeutics
Molecular Systems Biology
Nature Reviews (multiple)
Naunyn-Schmiedeberg Archives of Pharmacology
Neurochemistry International
Neuroscience Letters
NMR in Biomedicine
OMICS: A Journal of Integrative Biology
Oncogene
Pediatrics
Pharmaceutical Research
Pharmacological Reviews
PLoS
Radiation Research
Science
Technology in Cancer Research and Treatment
Toxicology
Toxicology and Applied Pharmacology
Editorial Board:
Cancer Metabolomics (Editor-inChief)
Recent Patents on Medical Imaging
ISRN Molecular Imaging
Consultant or Service as a Professional Expert
1999- Novartis Pharma AG
2002 Isotechnika
2003 Sanofi-Synthelabo Research
2003 Roche Bioscience
2003 AstraZeneca Pharmaceuticals
2003 Progen
2004- SIDMAP Inc. (member for the Scientific Advisory Board)
2006- Eli Lilly and Company
2007- Imclone
2008- OSI
2009- Facet
2010- Genentech
2010- Array Pharmaceuticals
Publications
1) Books and Book Chapters
1.1) Serkova N: Effects of immunosuppressive drugs on cell metabolism of neuronal and gill cell lines by
multinuclear magnetic resonance spectroscopy (German). ISBN 3-8265-2124-2, Shaker Verlag, Aachen,
1997.
1.2) Serkova NJ and Glunde K: “Metabolomics in cancer” in Tumor Biomarker Discovery series Methods in
Molecular Biology, ISBN 978-1-60327-810-2, Springer, 2009.
1.3) Serkova NJ, Hasebroock KM, Kraft SL: “Magnetic resonance spectroscopy of living tissues” in Tumor
Biomarker Discovery series Methods in Molecular Biology, ISBN 978-1-60327-810-2, Springer, 2009.
1.4) Boyes SG, Rowe MD, Chang CC, Thamm DH, Kraft SL, Harmon JF, Serkova NJ, Vogt AP, Sumerlin
BS: “Surface modification of positive contrast nanoparticle agents with RAFT polymers towards the
targeted imaging and treatment of cancer” in Polymeric Delivery of Therapeutics (by S. Morgan and R.
Lochhead), ISBN13: 978-084-122-5831, Oxford University Press, 2011.
2)
Peer-Reviewed Articles
B. Selected peer-reviewed publications (total 97):
2.1) Flögel U, Niendorf T, Serkowa N, Brand A, Henke J, Leibfritz D: Change in organic solutes, volume,
energy state, and metabolism associated with osmotic stress in glial cell line: A multinuclear NMR study.
Neurochem Res 20: 793-802, 1995 [PMID 7477672]
2.2) Serkova N, Brand A, Christians U, Leibfritz D: Evaluation of the effects of immunosuppressants on
neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy. Biochim Biophys Acta
1314: 93-104, 1996 [PMID 8972722].
2.3) Serkova N, Christians U, Flögel U, Pfeuffer J, Leibfritz D: Assessment of the mechanism of astrocyte
swelling induced by the macrolide immunosuppressant sirolimus using multinuclear magnetic resonance
(NMR) spectroscopy. Chem Res Toxicol 10: 1359-1363, 1997 [PMID 9437526].
2.4) Serkova N, Litt L, James TL, Sadee W, Leibfritz D, Benet LZ, Christians U: Evaluation of individual and
combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear
NMR spectroscopy. J Pharmacol Exp Ther 289: 800-806, 1999 [PMID 10215655].
2.5) Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ,
Schuler W, Morris RE: Combined immunosuppression with cyclosporine (NeoralR) and SDZ RAD in nonhuman primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and
tolerability. Transplantation 69: 76-86, 2000 [PMID 10653384].
2.6) Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W,
Schreier MH, Morris RE: Prevention of acute allograft rejection in nonhuman primate lung transplant
recipients: Induction with chimeric anti-IL-2 receptor monoclonal antibody improves the tolerability and
potencies the immunosuppressive activity of a regimen using low doses of both microemulsion
cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation 69: 488-496, 2000 [PMID
10708100].
2.7) Serkova N, Litt L, Leibfritz D, Hausen B, Morris RE, James TL, Benet LZ, Christians U: The novel
immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of highenergy phosphates. Br J Pharmacol 129: 485-492, 2000 [PMID 10711346].
2.8) Serkova N, Hausen B, Jacobsen W, Berry GJ, Morris RE, Benet LZ, Christians U: Tissue distribution
and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD in primate lung transplant
recipients: Interaction with cyclosporine. J Pharmacol Exp Ther 294: 323-332, 2000 [PMID 10871329].
2.9) Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI:
Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass
spectrometry: Immunosuppressants. J Chromatogr B Biomed Sci Appl 748: 41-53, 2000 [PMID
11092585].
2.10) Ikonen TS, Gummert JF, Serkova N, Hayase M, Honda Y, Kobayase Y, Hauser B, Yock PG, Christians
U, Morris RE: Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in nonhuman primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal
thickening. Transpl Int 13: 314-320, 2000 [PMID 11112022].
2.11) Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U: Comparison of the in vitro
metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 33: 514-515,
2001 [PMID 11266932].
2.12) Serkova N, Jacobsen W, Niemann CU, Benet LZ, Leibfritz D, Christians U: Sirolimus, but not structurally
related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in
the rat brain. Br J Pharmacol 133: 875-885, 2001 [PMID 11454661].
2.13) Serkova N, Donohoe P, Gottschalk S, Hainz C, Niemann CU, Bickler PE, Litt L, Benet LZ, Leibfritz D,
Christians U: Comparison of the effects of cyclosporine A on the metabolism of perfused rat brain slices
during normoxia and hypoxia. J Cereb Blood Flow Metab 22: 342-352, 2002 [PMID 11891440].
2.14) Niemann CU, Saeed M, Akbari H, Jacobsen W, Benet LZ, Christians U, Serkova N: Close association
between the reduction in myocardial energy metabolism and infarct size: dose response assessment of
cyclosporine. J Pharmacol Exp Ther 302: 1123-1128, 2002 [PMID 12183671].
2.15) Niemann CU, Stabernack D, Serkova N, Jacobsen W, Christians U, Eger EI: Cyclosporine can increase
isoflurane MAC. Anesth Analg 95: 930-934, 2002 [PMID 12351270].
2.16) Serkova N, Bendrick-Peart J, Alexander B, Tissot van Patot MC: Metabolite concentrations in human
term placentae and their changes due to delayed collection after delivery. Placenta 24: 227-235, 2003
[PMID 12566250].
2.17) Serkova N, Klawitter J, Niemann CU: Organ-specific metabolic response to cyclosporine treatment in
rat liver, kidney and heart. Transplant Int 16: 748-755, 2003 [PMID 12827232].
2.18) Wischmeyer PE, Jayakar D, Williams U, Singleton KD, Riehm J, Bacha EA, Jeevanandam V, Christians
U, Serkova N: Single dose of glutamine preserves myocardial tissue metabolism, glutathione content,
and enhances myocardial function following ischemia-reperfusion injury. J Parenter Enternal Nutr 27:
396-403, 2003 [PMID 14621120].
2.19) Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat
kidney transplants after ischemia/ reperfusion injury. Transplantation 76: 1594-1599, 2003 [PMID
14702530].
2.20) Serkova N and Christians U: Transplantation: Toxicokinetics and mechanisms of toxicity of cyclosporine
and macrolides. A review. Curr Opinion Invest Drugs 4: 1287-1296, 2003 [PMID 14758767].
2.21) Fuller TF, Serkova N, Niemann CU, Freise CE: Influence of donor pretreatment with N-acetylcysteine on
ischemia/reperfusion injury in rat kidney grafts. J Urol 171: 1296-1300, 2004 [PMID 14767336].
2.22) Serkova NJ, Christians U, Benet LZ: Biochemical mechanisms of cyclosporine neurotoxicity. A review.
Mol Interv 4: 97-107, 2004 [PMID 15087483].
2.23) Tissot van Patot MC, Bendrick-Peart J, Beckey VE, Serkova N, Zwerdlinger L: Greater vascularity,
lowered HIF-1/DNA binding, and elevated GSH as markers of adaptation to in vivo chronic hypoxia. Am J
Physiol Lung Cell Mol Physiol 287: 525-532, 2004 [PMID 15132953].
2.24) Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N: Alterations in glucose
metabolism by cyclosporine link to oxidative stress in rat brain slices: interactions with mTOR inhibitors.
Br J Pharmacol 143: 388-396, 2004 [PMID 15339861].
2.25) Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ: Imatinib (STI571)-mediated changes in
glucose metabolism in human leukemia BCR-ABL positive cells. Clin Cancer Res 10: 6661-6668, 2004
[PMID 15475456].
2.26) Boros LG, Serkova NJ, Cascante MS, Lee WNP: Use of metabolic pathway flux information in targeted
cancer drug design: A review. Drug Discov Today 1: 435-443, 2004.
2.27) Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU: 1H-NMR-based metabolic signatures of mild
and severe ischemia/ reperfusion injury in rat kidney transplants. Kidney Int 67: 1142-1151, 2005 [PMID
15698456].
2.28) Singleton KD, Serkova N, Banerjee A, Meng X, Gamboni-Robertson F, Wischmeyer PE: Glutamine
attenuates endotoxin-induced lung metabolic dysfunction: Potential role of enhanced heat shock protein
70. Nutrition 21: 214-223, 2005 [PMID 15723751].
2.29) Singleton KD, Serkova N, Beckey VE, Wischmeyer PE: Glutamine attenuates lung injury and improves
survival following sepsis: Role of enhanced heat shock protein expression. Crit Care Med 33: 1206-1213,
2005 [PMID 15942332].
2.30) Serkova N and Boros LG: Detection of resistance to imatinib by metabolic profiling: Clinical and drug
development implication: A review. Am J Pharmacogenomics 5: 293-302, 2005 [PMID 16196499].
2.31) Niemann CU, Hirose R, Liu T, Behrends M, Brown JL, Kominsky D, Roberts JP, Serkova N: Ischemic
preconditioning improves energy state and transplantation survival in obese Zucker rat livers. Anesth
Analg 101: 1577-1583, 2005 [PMID 16301222].
2.32) Serkova N and Christians U: Biomarkers for toxicodynamic monitoring of immunosuppressants: NMRbased quantitative metabonomics of the blood. Ther Drug Monit 27: 733-737, 2005 [PMID 16404806].
2.33) Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, Maher JJ, Niemann CU: Metabolic
profiling of livers and blood from obese Zucker rats. J Hepatol 44: 956-962, 2006 [PMID 16223541].
2.34) Behrends M, Hirose R, Serkova NJ, Coatney JL, Bedolli M, Yardi J, Park YH, Niemann CU: Mild
hypothermia reduces the inflammatory response and hepatic ischemia/ reperfusion injury in rats. Liver Int
26: 734-741, 2006 {PMID 16842331].
2.35) Peng ZY, Serkova NJ, Kominsky DJ, Brown JL, Wischmeyer PE: Glutamine-mediated attenuation of
cellular metabolic dysfunction and cell death following injury is dependent on heat shock factor-1
expression. J Parenter Enteral Nutr 30: 373-378, 2006 [PMID 16931604].
2.36) Niemann CU, Choi S, Behrends M, Hirose R, Noh J, Coatney JL, Roberts JP, Serkova NJ, Maher JJ:
Mild hypothermia protects obese rats from fulminant hepatic necrosis induced by ischemia-reperfusion.
Surgery 140: 404-412, 2006 [PMID 16934602].
2.37) Serkova NJ and Niemann CU: Pattern recognition and biomarker validation using quantitative 1H-NMR
based metabolomics: A review. Expert Rev Mol Diagn 6: 717-731, 2006 [PMID 17009906].
2.38) Glunde K and Serkova NJ: Therapeutic targets and surrogate markers in choline phospholipid
metabolism in cancer: A review. Pharmacogenomics 7: 1109-1123, 2006 [PMID 17054420].
2.39) Park Y, Hirose R, Coatney JL, Ferell L, Behrends M, Roberts JP, Serkova NJ, Niemann CU: The effect
of aging on warm ischemia reperfusion injury in the rat liver. J Surg Res 137: 96-102, 2007 [PMID
17064732].
2.40) Rudolph MC, McManaman JL, Phang TL, Anderson SM, Russell T, Kominsky DJ, Serkova NJ, Neville
MC: Metabolic regulation in the lactating mouse: A milk lipid synthesizing machine. Physiol Genomics
28: 323-326, 2007 [PMID 17105756].
2.41) Serkova NJ, Zhang Y, Coatney JL, Hunter L, Wachs M, Niemann CU, Mandell SM: Early detection of
graft failure using the blood metabolic profile of a liver recipient. Transplantation 83: 517-521, 2007
[PMID 17318087].
2.42) Serkova NJ, Rose JC, Epperson LE, Carey HV, Martin SL: Quantitative analysis of liver metabolites in
three stages of the circannual hibernation cycle in 13-lined ground squirrels by NMR. Physiol Genomics
31: 15-24, 2007 [PMID 17536023].
2.43) Niemann CU and Serkova NJ: Biochemical mechanisms of nephrotoxicity: Application for
metabolomics: A review. Exp Opin Drug Metab Toxicol 3: 527-544, 2007 [PMID 17696804].
2.44) Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello
F, Eckhardt SG: Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of VEGFR
and EGFR signaling, in combination with irinotecan in human colon cancer xenograft model. Clin Cancer
Res 13: 6450-6458, 2007 [PMID 17975157].
2.45) Khan SR, Herman J, Krank J, Serkova NJ, Churchill MEA, Suga H, Farrand SK: PhzR, the quorumsensing regulator of phenazine gene expression in Pseudomonas chlororaphis strain 30-84 responds to
N-(3-hydroxy-hexanoyl)-L-homoserine lactone and N-hexanoyl)-L-homoserine lactone with equal
sensitivity. Appl Environ Micribiol 73: 7443-7455, 2007 [PMID 17921283].
2.46) Serkova NJ, Spratlin JL, Eckhardt SG: NMR-based metabolomics: Translational application and
treatment of cancer: A review. Curr Opin Mol Ther 9: 572-585, 2007 [PMID 18041668].
2.47) Serkova NJ, Reisdorph NA, Tissot van Patot MC: Metabolic markers of hypoxia: Systems biology
application in biomedicine. Toxicol Mech Methods 18: 81-95, 2008 [20020894].
2.48) Serkova NJ, Gamito EJ, Jones RH, O’Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford
ED: The metabolites citrate, myo-inositol, and spermine are potential age-dependent markers of prostate
cancer in human expressed prostatic secretions. Prostate 68: 620-628, 2008 [PMID 18213632].
2.49) Serkova NJ, Van Rheen Z, Tobias M, Pitzer J, Wilkinson JE, Stringer KA: Utility of magnetic resonance
imaging and nuclear magnetic resonance-based metabolomics for the quantification of inflammatory lung
injury. Am J Physiol Lung Cell Mol Physiol 295: L152-L161, 2008 [PMID 18441091].
2.50) Larsen BA, Haag MA, Serkova NJ, Shroyer KR, Stoldt CR: Controlled aggregation of
superparamagnetic iron oxide nanoparticles for the development of molecular magnetic resonance
imaging probes. Nanotechnology 19: 265-271, 2008 [PMID 21828671].
2.51) Young CD, Nolte E, Lewis A, Serkova NJ, Anderson SM: Activated Akt1 accelerates MMTV-c-ErbB2
mammary tumorigenesis inc mice without activation of ErbB3. Breast Cancer Res 10: R70, 2008 [PMID
18700973].
2.52) Lam ET, O’Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden S, Dancey J, Eckhardt
SG, Gore L: A phase I study of gefitinib, capecitabine, and celexocib in patients with advanced solid
tumors. Mol Cancer Ther 7: 3685-3694, 2008 [PMID 19074845].
2.53) Serkova NJ, Freud AS, Brown JL, Kominsky DJ: Use of the 1-mm TXI micro-probe for metabolic
analysis on small volume biological samples. J Cell Mol Med 13: 1933-1941, 2009 [PMID 19267884].
2.54) Frey LC, Hellier J, Unkart C, Lepkin A, Hasebroock K, Serkova N, Liang LP, Patel M, Soltesz I, Staley K:
A novel apparatus for lateral fluid percussion injury in the rat. J Neurosci Methods 177: 267-272, 2009
[PMID 19022291].
2.55) Spratlin JL, Serkova NJ, Eckhardt SG: Clinical application of metabolomics in oncology: a review. Clin
Cancer Res 15: 431-440, 2009 [PMID 19147747].
2.56) Serkova NJ, Garg K, Bradshaw-Pierce EL: Oncologic imaging endpoints for the assessment of therapy
response. Recent Pat Anticancer Drug Discov 4: 36-53, 2009 [PMID 19149687].
2.57) Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, Serkova NJ: Timedependent effects of imatinib in human leukaemia cells: A kinetic NMR-profiling study. Br J Cancer 100:
923-931, 2009 [PMID 19259085].
2.58) Tissot van Patot MC, Serkova NJ, Haschke M, Kominsky DJ, Roach RC, Sheen P, Christians U,
Henthorn TK, Honigman B: Enhanced leukocyte HIF-1alpha and HIF-1 DNA-binding in humans following
rapid ascent to 4300 m. Free Radic Biol Med 46: 1551-1557, 2009 [PMID 19303436].
2.59) Raina K, Serkova NJ, Agarwal R: Silibinin feeding alters the metabolic profile in TRAMP prostatic
tumors: 1H-NMRS-based metabolomics study (Priority Report). Cancer Res 69: 3731-3735, 2009 [PMID
19366793].
2.60) Hasebroock KM, Serkova NJ: Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol
5: 403-416, 2009 [PMID 19368492].
2.61) Serkova NJ, Glunde K: Metabolomics in cancer. Methods Mol Biol 520: 273-295, 2009 [PMID
19381962].
2.62) Serkova NJ, Hasebroock KM, Kraft SL: Magnetic resonance spectroscopy of living tissues. Methods Mol
Biol 520: 315-327, 2009 [PMID 19381964].
2.63) Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ: Abnormalities in
glucose uptake and metabolism in imatinib-resistant human BCR-ABL positive cells. Clin Cancer Res 15:
3442-3450, 2009 [PMID 19401345].
2.64) Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U: Development and validation
of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell
culture. Biomed Chromatogr 23: 1251-1258, 2009 [PMID 19517424].
2.65) Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG,
Serkova NJ: Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J
Pharmacol 158: 588-600, 2009 [PMID 19663881].
2.66) Tissot van Patot MC, Murray AJ, Beckey V, Cindrova-Davies T, Johns J, Zwerdlinger L, Jauniaux ER,
Burton GJ, Serkova NJ: Human placental adaptation to chronic hypoxia, high altitude: Hypoxic preconditioning. Am J Physiol Regul Integr Comp Physiol 298: R166-172, 2010 [PMID 19864339].
2.67) Serkova NJ: Imaging biochemistry non-invasively: Magnetic resonance spectroscopy in liver disease.
Editorial. J Parenter Enteral Nutr 33: 826-728, 2009 [PMID 19892909].
2.68) Merz AL and Serkova NJ: Use of NMR-based metabolomics in detecting drug resistance in cancer.
Biomark Med 3: 289-306, 2009 [PMID 20160999].
2.69) Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ,
Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG:
Phase I pharmacologic and biologic study of Ramucirumab (IMC-1121B), a fully human immunoglobulin
G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28: 780787, 2010 [PMID 20048182].
2.70) Klawitter J, Gottschalk S, Hainz C, Leibfritz D, Christians U, Serkova NJ: Immunosuppressant
neurotoxicity in rat brain models: Oxidative stress and cellular metabolism. Chem Res Tox 23: 608-619,
2010 [PMID 20148532].
2.71) Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM,
Thurman JM: Renal inflammation: Targeted iron oxide nanoparticles for molecular MR imaging in mice.
Radiology 255: 517-526, 2010 [PMID 20332377].
 Editorial: Mahmood U: Science to practice: can a targeted nanoparticle be used to image
autoimmune nephritis? Radiology 255: 309-310, 2010 [PMID 20413745].
2.72) Doctor RB, Serkova NJ, Hasebroock KM, Zafar I, Edelstein CL: Distinct patterns of kidney and liver cyst
growth in pkd2(WS25-/-) mice. Nephrol Dial Transplant 25: 3496-3504, 2010 [PMID 20388629].
2.73) Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC,
Bray MR, Eckhardt SG: Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted
kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin
Cancer Res 16: 2989-2998, 2010 [PMID 20406842].
2.74) Vincenti M, Behrends M, Dang K, Park YH, Hirose R, Blasi-Ibanez S, Liu T, Serkova NJ, Niemann CU:
Induction of intestinal ischemia reperfusion injury by portal vein outflow occlusion in rats. J Gastroenterol
45: 1103-1110, 2010 [PMID 20549254].
2.75) Cohen MJ, Serkova NJ, Wiener-Kronish J, Pittet JF, Niemann CU: 1H-NMR-based metabolic signatures
of clinical outcomes in trauma patients – beyond lactate and base deficit. J Trauma 69: 31-40, 2010
[PMID 20622576].
2.76) Boyes SG, Rowe MD, Serkova NJ, Kim FJ, Lambert JR, Werahera PN: Polymer-modified gadolinium
nanoparticles for targeted magnetic resonance imaging and therapy. NanoLife 1: 263-275, 2010.
2.77) Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine R III, Standiford TJ: Metabolic consequences of
sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative
metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 300: L4-L11, 2011 [PMID
20889676].
2.78) Martinez-Palli G, Hirose R, Liu T, Xu F, Dang K, Serkova NJ, Niemann CU: Donor-pretreatment with
everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant
model. Nephrol Dial Transplant 26: 1813-1820, 2011 [PMID 21068143].
2.79) Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ: Age and sex differences in
the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.
Neurotoxicology 32: 50-57, 2011 [PMID 21075140].
2.80) Ramasamy K, Nield L, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, Singh RP, Malkinson AM,
Agarwal R: Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: Potential of realtime microCT in lung cancer chemoprevention studies. Clin Cancer Res 17: 753-761, 2011 [PMID
21148748].
2.81) Hatakeyama WM, Sanchez TJ, Rowe MD, Serkova NJ, Liberatore MW, Boyes SG: Synthesis of
gadolinium nanoscale metal-organic framework with hydrotropes: Manipulation of particle size and
magnetic resonance imaging capability. ACS Appl Mater Interfaces 3: 1502-1510, 2011 [PMID
21456529].
2.82) Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, Eckhardt SG: Synergistic
results of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer
cell lines. Anticancer Res 31: 1093-1103, 2011 [PMID 21508352].
2.83) Serkova NJ: Translational imaging endpoints to predict treatment response to novel targeted anticancer
agents. Drug Resist Updat 14: 224-235, 2011 [PMID 21640633].
2.84) Serkova NJ, Standiford TJ, Stringer KA: The emerging field of quantitative blood metabolomics for
biomarker discovery in critical illnesses. Review. Am J Respir Crit Care Med 184: 647-655, 2011 [PMID
21680948].
 Comments: Bos LD, Sterk PJ, Schulz MJ: Measuring metabolomics in acute lung injury: choosing
the correct compartment? Am J Respir Crit Care Med 185: 789, 2012 [PMID 22467809].
2.85) Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C, McFann K, Pickering MC,
Thurman JM: Detection of glomerular complement C3 fragments by magnetic resonance imaging in
murine lupus nephritis. Kidney Int 81: 152-159, 2012 [PMID 21956190].
2.86) Morelli MP, Tentler JT, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy
S, Acaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG: Preclinical activity of the rational
combination of selumetinib (AZD6244) in combination with vorinostat in KRAS mutant colorectal cancer
models. Clin Cancer Res 18: 1051-1062, 2012 [PMID 22173548].
2.87) Serkova NJ, Brown MS: Quantitative analysis in magnetic resonance spectroscopy: from metabolic
profiling to in vivo biomarkers. Bioanalysis 4: 321-341, 2012 [PMID 22303835].
2.88) Beresford TP, Fay T, Serkova N, Wu PH: Immunophyllin ligands show differential effects on alcohol selfadministration in C57BL mice. J Pharmacol Exp Ther 341: 611-616, 2012 [PMID 22375069].
2.89) Larsen BA, Hurst KM, Ashurst WR, Serkova NJ, Stoldt CR: Mono and dialkoxysilane surface
modification of superparamagnetic iron oxide nanoparticles for application as magnetic resonance
imaging contrast agents. J Material Res 27: 1846-1852, 2012.
2.90) Raina K, Rajamanickam S, Ravichandran K, Huber KM, Serkova NJ, Agarwal R: Inositol hexaphosphate
inhibits tumor growth, vascularity, and metabolism in TRAMP mice: A multiparametric magnetic
resonance study. Cancer Res Prev 6: 40-50, 2013 [PMID 23213071]. - January 2013 Cancer Prev Res
Journal Cover Page Coverage.
2.91) Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J,
Desouza N, Leach M, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG,
Kaye S, Demetri G, Scurr M: First-in-human Phase I trial of two schedules of OSI-930, a novel
multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res 19: 909919, 2013 [PMID 23403628].
2.92) Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R: Energy deprivation by silibinin in colorectalcancer cells: A double edged sword targeting both apoptotic and autophagic machinery. Autophagy 9:
697-713, 2013 [PMID 23445752].
2.93) Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt
SG, Weekes CD: Utilization of quantitative pharmacology approach to assess the combination effects of
everolimus and irinotecan in murine xenograft models of colorectal cancer. PLoS One 8(3): e58089,
2013 [PMID 23520486].
2.94) Weitzel L, Ambardekar AV, Brieke A, Cleveland JC, Serkova NJ, Wischmeyer PE, Lowes BD: Left
ventricular assist device effects on metabolic substrates in the failing heart. PLoS One 8(4): e60292,
2013 [PMID 23560088].
2.95) Derry M, Raina K, Balaiya V, Jain AK, Shrotriya S, Huber KM, Serkova NJ, Agarwal R, Agarwal C:
Grape seed extract efficacy against azoxymethane-induced colon tomorigenesis in A/J mice: Interlinking
miRNA with cytokine signaling and inflammation. Cancer Res Prev 6(7): 625-633, 2013 [PMID
23639480].
2.96) Wilson J, Higgins D, Hutting H, Serkova N, Baird C, Khailova L, Queensland K, Weitzel L, Tran ZV,
Wischmeyer PE: Early propranolol treatment induces lung heme-oxygenase-1, attenuates metabolic
dysfunction, and improves survival following experimental sepsis. Crit Care 2013 Sep 10; 17(5): R195.
[Epub ahead of print] [PMID 24020447].
2.97) Epple LM, Dodd RD, Merz AL, Dechkovskaia AM, Herring M, Winston BA, Lencioni AM, Russell RL,
Madsen H, Nega M, Dusto NL, White J, Bigner DD, Nicchitta CV, Serkova NJ, Graner MW: Induction of
the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS
One 8(8): e73267, 2013 [PMID 24039668].
2.98) Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler
E, Flaig TW: Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and
bladder urothelial hyperplasia. PLoS One 8(9): e74809, 2013 [PMID 24058630].
2.99) Serkova NJ: New advances and state-of-the-art MR spectroscopy in oncology. Current Molecular
Imaging [in press].
2.100)Thurman JM, Serkova NJ: Nano-sized contrast agents to non-invasively detect renal inflammation.
Journal of Renal Disease [in press].
Submitted Manuscripts:
2.101)Epple LM, Dodd RD, Merz AL, Dechkovskaia AM, Herring M, Winston BA, Nega M, Dusto NL, White J,
Bigner DD, Serkova NJ, Graner MW: The unfolded protein response drives enhanced metabolism and
chemoresistance in glioma cells. PLoS ONE.
2.102)Alvarez-Calderon F, Gregory MA, Zaberezhnyy V, Gemta L, Serkova N, DeGregori: “BCR-ABL
inhibition results in mitochondrial metabolic addictions in leukemia” to Blood.
2.103)Serkova NJ, Boyes SG: Development of targeted nanoparticles for molecular imaging. Expert Opinion
on Drug Metabolism and Toxicology [in press].
Manuscripts In Preparation:
2.104)Serkova NJ, Bradshaw-Pierce EL, Huber KM, Merz AL, Pitts TM, Eckhardt SG: “Multiparametric
imaging response to IGF1R inhibition in mouse colorectal cancer models” to Clinical Cancer Research.
2.105)Bluth JS, Loram LC, Brown MS, Huber KM, Miller DE, Watkins LR, Serkova NJ: ”Magnetic resonance
imaging (MRI) detection of spinal lesions ina rat MS model” to Magnetic Resonance in Medicine.
2.106)Kominsky DJ, Brown JL, Bradshaw-Pierce EL, Frederick B, Raben D, Gustafson DL, Serkova NJ:
“EGFR- and VEGFR-mediated metabolic response in human head and neck carcinoma models” to
Cancer Research.
2.107)Bradshaw-Pierce EL, Rowe M, Huber KM, Merz AL, Boyes S, Serkova NJ: “Molecular magnetic
resonance imaging (MRI) of EGFR using targeted gadolinium nanoparticles” to Clinical Cancer
Research.
2.108)Klawitter J, Trump S, Morrow M, Brown JL, Eckhardt SG, Serkova NJ: “Metabolic signature of the
EGFR inhibitor gefitinib in combination with 5-FU in human colorectal cancel cell lines” to Clinical Cancer
Research.
2.109)Coatney JL, Bradshaw-Pierce EL, Hasebroock KM, Levi M and Serkova NJ: “Dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) to assess renal functions in 5/6 mouse nephrectomy
model” to Magnetic Resonance in Medicine.
2.110)Bradshaw-Pierce EL, Huber KM, Merz AL, Serkova NJ: “Multiparametric imaging and NMR
metabolomics to assess effects of enzastaurine in mouse colorectal xenografts” to Clinical Cancer
Research.
2.111)Wise-Faberowski L, Kominsky DJ, Peluso B, Beckey VE, Serkova NJ: “The age-dependent response
to hypoxia in the rat: 1H- and 31P-NMR metabolomics study” to Brain Research.
2.112)Niemann CU, Karnovsky A, Dang K, Merz AL, Serkova NJ: “Metabolic profiles of renal ischemiareperfusion injury in acute and prolonged hyperglycemic rats” to Journal of Proteome Research.
2.113)Serkova NJ, Robinson D, Merz AL, Huber KM, Bradshaw-Pierce EL: “TWEAK inhibition results in
decreased glucose uptake by FDG-PET and lipid accumulation by NMR-metabolomics in mouse lung
xenografts” to Clinical Cancer Research.
2.114)Serkova NJ, Smith-Jones P, Aboagye E: “Animal Multimodality Imaging” to Radiology.
2.115)Serkova NJ, McClure WC, Huber KM, Tseng BS: “Gadolinium-enhanced T1-MRI pinpoints skeletal
muscle pathologyand metabolic dysfunctions in dystrophin deficient mice” to Magnetic Resonance in
Medicine.
2.116)Habekorn C, Garcia L, Merz AL, Pitts T, Eckhardt SG, Serkova NJ: “Metabolic signature of IGF1Rpathway inhibition in colorectal cancer cells” to Clinical Cancer Research.
2.117)Anderson N, Klawitter J, Merz AL, Druker B, Eckhardt SG, Serkova NJ: “Role of BCR-ABL in metabolic
re-programing” to Clinical Cancer Research.
2.118)Serkova NJ, Eckhardt SG: “Metabolic signature of signal transduction inhibition” to Clinical Cancer
Research.
2.119)Reisdorph N, Prenni J, Kechris K, Serkova NJ: “Multi-platform metabolomics: From the collection to the
analysis” to Analytical Biochemistry.
2.120)Serkova NJ, Coatney JL, Karnovsky A, Geselkovich M, Lapin W, Cromer D, Mandell MS, Niemann CU:
“Blood metabolomics in renal transplant patients” to Journal of Clinical Investigations.
2.121)DeRyckere D, Macy ME, Huber KM, Gardner LA, Jedlika P, Merz AL, Gore L, Serkova NJ: “Lipogenesis
and metabolic re-programing correlates with decreased T1-relaxation time and leukogenesis in MLL-AF9
transgenic mice” to Magnetic Resonance in Medicine.
2.122)Frey L, Lepkin A, Schickedanz A, Hasebroock KM, Brown MS, Serkova NJ: “ADC mapping and T1weighted signal changes on post-injury MRI predict seizure susceptibility and gross vestibulomotor
outcome after experimental brain injury” to Journal of Cerebral Blood Flow and Metabolism.
2.123)Serkova NJ, Merz AL, Wilson L, Weekes CD: “Metabolic response to mTOR inhibition in pancreatic
cancer cell lines” to Clinical Cancer Research.
2.124)Serkova NJ: “Tissue metabolome: Effects of various extractions on quantitative NMR-metabolomics” to
Bioanalysis.
3) Peer-Reviewed Conference Abstracts
3.1) Brand, A., Flögel, U., Richter-Landsberg, C., Serkowa, N., Leibfritz, D.: Mechanism of osmoregulation in
neuronal and glial cells in culture: A multinuclear magnetic resonance study. International Society of
Development in Neuroscience, San Diego, CA, August 1.-5., 1994.
3.2) Flögel, U., Niendorf, T., Serkowa, N., Brand, A., Henke, J., Leibfritz, D.: The role of organic solutes in
volume-/osmoregulation of glial cells. 2nd Meeting of the Society of Magnetic Resonance, San Francisco,
CA, August 6.-12., 1994
3.3) Leibfritz, D., Flögel, U., Niendorf, T., Serkowa, N., Brand, A.: On line monitoring of cell volume and
osmolyte concentrations in glial and neuronal cells after osmotic stress by multinuclear magnetic
resonance spectroscopy, EUSEB Meeting: Basic and Clinical Neuroscience 93, Prague, Czech,
September 12.-17., 1994.
3.4) Serkowa, N., Leibfritz, D.: Einfluß von Immunsuppressiva auf neuronale und gliale Zellinien
nachgewiesen mit NMR. 16th Symposium of the GDCh-Schwerpunkt: Magnetische Resonanz an
biologischen Systemen, Witzenhausen, Germany, September 28.-October 1., 1994.
3.5) Flögel, U., Brand, A., Serkowa, N., Niendorf, T., Leibfritz, D.: Untersuchungen zur Osmo- und
Volumenregulation von Zellen mittels NMR-Spektroskopie. 16th Symposium of the GDCh-Schwerpunkt:
Magnetische Resonanz an biologischen Systemen, Witzenhausen, Germany, September 28.-October 1.,
1994.
3.6) Brand, A., Serkowa, N., Flögel, U., Leibfritz, D.: Volume-/osmoregulation in primary neurons and
astrocytes in culture. 3rd Scientific Meeting of the Society of Magnetic Resonance, Nice, France, August
19.-25., 1995.
3.7) Serkowa, N., Brand, A., Leibfritz, D.: Metabolic response of primary astrocytes on immunosuppressive
stress. 3rd Scientific Meeting of the Society of Magnetic Resonance, Nice, France, August 19.-25., 1995.
3.8) Serkova, N., Pfeuffer, J., Flögel, U., Leibfritz, D.: Astrocyte swelling and changes in metabolite
concentrations during immunosuppressive stress. 4th Scientific Meeting of the Society of Magnetic
Resonance, New York, NY, April 27.-May 3., 1996.
3.9) Serkova, N., Flögel, U., Pfeuffer, J., Leibfritz, D.: Volume regulation and metabolic alterations in primary
astrocytes upon osmotic stress. 4th Scientific Meeting of the Society of Magnetic Resonance, New York,
NY, April 27.-May 3., 1996.
3.10) Pfeuffer, J., Flögel, U., Serkova, N., Dreher, W., Leibfritz, D.: Restricted diffusion and exchange of water
in perfused cell cultures studied by two-dimensional MR measurements. 4th Scientific Meeting of the
Society of Magnetic Resonance, New York, NY, April 27.-May 3., 1996.
3.11) Serkova, N., Flögel, U., Pfeuffer, J., Leibfritz, D.: NMR application to the evaluation of volume regulation
in primary astrocytes under pathological conditions, 13th European Experimental N.M.R. Conference,
Paris, France, May 19.-24., 1996.
3.12) Serkova, N., Flögel, U., Pfeuffer, J., Brand, A., Leibfritz, D.: Astrocyte swelling and metabolic alterations
upon osmotic stress by multinuclear MRS. 11th European Society for Neurochemistry Meeting,
Groningen, Netherlands, June 15.-20., 1996.
3.13) Pfeuffer, J., Flögel, U., Serkova, N., Dreher, W., Leibfritz, D.: Water diffusion measurements in perfused
cell cultures: Can mercurials induce permeability changes in glial cells? 13th Annual Meeting European
Society for Magnetic Resonance in Medicine and Biology, Prague, Czech, September 12.-15., 1996.
3.14) Serkova, N., Pfeuffer, J., Flögel, U., Christians, U., Leibfritz, D.: The mechanisms of astrocyte swelling
induced by the immunosuppressant cyclosporine: A multinuclear NMR study. 16th International Society of
Neurochemistry Meeting, Boston, MA, July 20.-26., 1997.
3.15) Serkova, N., Pfeuffer, J., Flögel, U., James, T., Leibfritz, D., Christians, U.: Neurotoxic effects of
immunosuppressants investigated by multinuclear NMR spectroscopy in vitro. 5th International Congress
of Therapeutic Drug Monitoring and Clinical Toxicology, Vancouver, Canada, November 10.-14., 1997.
3.16) Serkova, N., Litt, L., Leibfritz, D., Morris, R.E., Benet, L.Z., Christians, U., James, T.L.: Using 31P-NMR
spectroscopy of brain slices to determine neurotoxicity of novel immunosuppressants. 8th International
Conference on Magnetic Resonance in Biological Systems, Tokyo, Japan, August 23.-28., 1998.
3.17) Serkova, N., James, T.L., Benet, L.Z., Christians, U.: Neurotoxicity of novel macrolide
immunosuppressants in rat brain slices: combination with cyclosporine. 1998 American Association of
Pharmaceutical Scientists (AAPS) Annual Meeting, San Francisco, CA, November 15.-19., 1998.
3.18) Christians, U., Serkova N.: Erwünschte und unerwünschte Wirkungen von Immunsuppressiva –
Basieren Immunsuppression und Toxizität auf demselben molekularen Mechanismus? Früjahrstatung
der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz,
Germany, March 9.-12., 1999.
3.19) Serkova, N., Litt, L., James, T.L., Morris, R.E., Benet, L.Z., Christians, U.: Role of calcineurin and
immunophilins in the decrease of brain energy metabolism caused by immunosuppressants. 38th Annual
Meeting of the Society of Toxicology (SOT), New Orleans, LO, March 14.-18., 1999.
3.20) Ikonen, T.S., Gummert, J.F., Honda, Y., Hayase, M., Kobayashi, Y., Hausen, B.A., Barlowm C.W.,
Pelroth, J.D., Serkova, N., Christians, U., Fitzgerald, P., Berry, G.J., Yock, P.G., Morris, RE.: Sirolimus
(rapamycin) reverses the of graft vascular disease in non-human primate recipients of aortic allografts.
19th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT), San
Francisco, CA, April 21.-24., 1999.
3.21) Serkova, N., Litt, L., Leibfritz, D., James, T.L., Benet, L.Z., Christians, U.: Preclinical 31P-MRS
assessment of the neurotoxic potential and drug interaction of immunosuppressants used in organ
transplantation. 7th Scientific Meeting of the International Society of Magnetic Resonance in Medicine
(ISMRM), Philadelphia, MD, May 22.-28., 1999.
3.22) Serkova, N., Litt, L., Leibfritz, D., James, T.L., Benet, L.Z., Christians, U.: The novel immunosuppressant
SDZ-RAD antagonizes cyclosporine-induced reduction of brain energy. 6th International Congress of
Therapeutic Drug Monitoring and Clinical Toxicology, Cairns, Australia, September 13.-17., 1999.
3.23) Serkova, N., Hausen, B., Morris, R.E., Benet, L.Z., Christians, U.: Tissue distribution of the novel
macrolide immunosuppressant SDZ-RAD: Interaction with cyclosporine. 6th International Congress of
Therapeutic Drug Monitoring and Clinical Toxicology, Cairns, Australia, September 13.-17., 1999.
3.24) Christians, U., Jacobsen, W., Serkova, N., Baner, K., Benet, L.Z.: An automated, specific assay to
quantify cyclosporine and macrolide immunosuppressants in blood using LC/LC-MSD. 6th International
Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Cairns, Australia, September 13.-17.,
1999.
3.25) Serkova, N., Donohoe, P., Leibfritz, D., Benet, L.Z., Litt, L., Christians, U.: Metabolic neurotoxicity and
hypoxic neuroprotection of cyclosporine in brain slices: evidence that both occur from mitochondrial
interactions. 29th Annual Meeting of the Society for Neuroscience, Miami Beach, FL, October 23.-28.,
1999.
3.26) Jacobsen, W., Serkova, N., Hallensleben, K., Sewing, K., Benet, L.Z., Christians, U.: In vitro metabolism
of the novel immunosuppressant SDZ-RAD and comparison with rapamycin. 9th North American Meeting
of International Society of Study Xenobiotics (ISSX), Nashville, TN, October 24.-28., 1999.
3.27) Serkova, N., Jacobsen, W., Litt, L., Benet, L.Z., Leibfritz, D., Christians, U.: SDZ-RAD prevents inhibition
of brain energy metabolism: comparison with rapamycin. Transplant2000, 1st Joint Transplant Meeting of
the American Society of Transplantation (AST), Chicago, IL, May 13.-17., 2000.
3.28) Serkova, N., Basus, V., James, T.L., Litt, L.: [1-13C]Fructose-1,6-biphosphate protection of glucose
metabolism during hypoxia: 13C/1H-MRS on perfused rat brain slices. 19th International Conference on
Magnetic Resonance in Biological Systems, Florence, Italy, August 20.-25., 2000.
3.29) Serkova, N., Litt, L., Benet, L.Z., James, T.L., Leibfritz, D., Christians, U.: MRS evaluation of metabolic
neurotoxicity in the rat as a preclinical test for novel immunosuppressive drugs. 19th International
Conference on Magnetic Resonance in Biological Systems, Florence, Italy, August 20.-25., 2000.
3.30) Serkova, N., Jacobsen, W., Hausen, B., Morris, R.E., Benet, L.Z., Leibfritz, D., Christians, U.: RAD, but
not sirolimus, reverses the inhibition of brain metabolism by cyclosporine in the rat. 18th International
Congress of the Transplantation Society, Rome, Italy, August 27.-September 1., 2000.
3.31) Jacobsen, W., Serkova, N., Hausen, B., Morris, R., Benet, L., Christians, U.: Comparison of the in vitro
metabolism of the macrolide immunosuppressants sirolimus and RAD. 18th International Congress of the
Transplantation Society, Rome, Italy, August 27.-September 1., 2000.
3.32) Christians, U., Serkova, N., Leibfritz, D., Benet L.Z.: Novel immunosuppressive strategies in
transplantation medicine. 18th International Congress of the Transplantation Society, Rome, Italy, August
27.-September 1., 2000.
3.33) Serkova, N., Donohoe, P., Niemann, C.U., Litt, L., Benet, L.Z., Leibfritz, D., Christians, U.: Cyclosporinerelated mitochondrial effects in normoxia vs. hypoxia: 31P-MRS of perfused rat brain slices. 17th Annual
Meeting of the European Society for Magnetic Resonance in Medicine and Biology, Paris, France,
September 14.-17., 2000.
3.34) Litt, L., Hirai, K., Basus, V., Serkova, N., Develey, B., James, T.L.: Fructose-1,6-biphosphate protection
of glucose metabolism during hypoxia: 13C/ 1H/ 31P NMR studies of perfused rat brain slives at 14.1
Tesla. 30th Annual Meeting of the Society for Neuroscience, New Orleans, LO, November 4.-9., 2000.
3.35) Gottschalk, S., Hainz, S., Benet, L.Z., Leibfritz, D., Christians, U., Serkova, N: Metabolic neurotoxicity of
immunosuppressants in the rat: Correlation between MRS and biochemical findings. 40th Annual Meeting
of the Society of Toxicology, San Francisco, CA, March 25.-29., 2001.
3.36) Hainz, C., Gottschalk, S., Jacobsen, W., Benet, L.Z., Leibfritz, D., Christians, U., Serkova, N.: MRS
evaluations of metabolic changes by cyclosporine in rat brain: Role of the blood-brain-barrier. 40th Annual
Meeting of the Society of Toxicology, San Francisco, CA, March 25.-29., 2001.
3.37) Serkova, N., Donohoe, P., Gottschalk, S., Hainz, C., Christians, U., Leibfritz, D.: From metabolic
neurotoxicity to hypoxic neuroprotection: an MRS study of cyclosporine role in rat brain. 9th Scientific
Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Glasgow, Scotland,
UK, April 21.-27., 2001.
3.38) Serkova, N., Gottschalk, S., Hainz, C., Benet, L.Z., Leibfritz, D., Christians, U.: Metabolic nephrotoxicity
by cyclosporine in combination with macrolides: Comparison of SDZ-RAD vs. sirolimus. Transplant2001,
2nd Joint Transplant Meeting of the American Society of Transplantation (AST), Chicago, IL, May 11.-16.,
2001.
3.39) Jacobsen, W., Niemann, C., Unger, M., Serkova, N., Hirai, S., Benet, L.Z., Christians, U.: Automated,
fast and sensitive quantification of drugs in human plasma by LC/LC-MS: Protease inhibitors and nonnucleoside reverse transcriptase inhibitors. 2001 American Association of Pharmaceutical Scientists
(AAPS) Annual Meeting, Denver, CO, October 19.-26., 2001.
3.40) Serkova, N., Jacobsen, W., Leibfritz, D., Christians, U., Niemann, C.U.: Organ-specific metabolic
response to cyclosporine treatment in rat liver, kidney, and heart: is there an evidence of
preconditioning? 2nd Winter Symposium of the American Society of Transplant Surgeon (ASTS), Miami
Beach, FL, January 25.-27., 2002.
3.41) Serkova, N., Niemann, C.U., Saeed, M., Gottschalk, S., Benet, L.Z., Leibfritz, D., Christians. U.: Cardiac
energy depression by cyclosporine prior to occlusion protects rat heart during ischemic insult. 10th
Scientific Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Honolulu,
Hawaii, May 18.-24., 2002.
3.42) Gottschalk, S., Hainz, C., Leibfritz, D., Serkova, N.: MRS evaluations of the metabolic response of
human leukemia cells to a new tyrosine kinase inhibitor gleevec. 10th Scientific Meeting of the
International Society of Magnetic Resonance in Medicine (ISMRM), Honolulu, Hawaii, May 18.-24., 2002.
3.43) Gottschalk, S., Hainz, C., Miljus, J., Benet, L.Z., Christians, U., Leibfritz, D., Serkova, N.: Metabolic
response and free radical formation by cyclosporine and macrolide immunosuppressants in rat brain
slices. 14th World Congress of Pharmacology, San Francisco, CA, July 7.-12., 2002.
3.44) Wischmeyer, P.E., Singleton, K.D., Serkova, N.: Glutamine preserves ATP levels and decreases tissue
lactate in the myocardium following sublethal endotoxin shock. 25th Annual Conference on Shock, Big
Sky, MO, June 8.-11., 2002.
3.45) Singleton, K.D., Serkova, N., Song, Y., Banerjee, A., Meng, X., Camboni-Robertson, F., Wischmeyer,
P.E.: Glutamine enhances heat shock protein 72 expression and preserves high energy phosphate levels
in lung tissue following sublethal endotoxin shock. 25th Annual Conference on Shock, Big Sky, MO, June
8.-11., 2002.
3.46) Christians, U., Serkova, N.: Interaction and toxicity of calcineurin and TOR inhibitors. 19th International
Congress of Transplantation Society, Miami, FL, August 25.-30., 2002.
3.47) Serkova, N., Frisch, L.: MRS assessment on metabolic response to imatinib in human chronic
myelogenious leukemia cells. ISMRM Workshop on In Vivo Functional and Molecular Assessment of
Cancer, Santa Cruz, CA, October 18.-21., 2002.
3.48) Serkova, N., Christians, U., Henthorn, T.K.: Magnetic resonance (MRI/MRS) in biomedical research:
Metabonomics for drug efficacy and toxicity. BioExpo, Denver, CO, December 4., 2002
3.49) Wiscmeyer, P.E., Jayakar, D., Williams, U., Singleton, K.D., Serkova, N.: Sigle dose of glutamine
preserves myocardial tissue metabolism, glutathione content, and enhances myocardial function
following ischemia-reperfusion injury. Nutrition Week, San Antonio, TX, January 18.-22., 2003.
3.50) Singleton KD, Serkova N, Wischmeyer PE: Glutamine attenuates the metabolic dysfunction of sublethal
endotoxin shock via manipulation of the heat stress protein pathway. Shock Society Meeting, Phoenix,
AR, 2003.
3.51) Wischmeyer PE, Singleton KD, Serkova N: Glutamine attenuates sepsis-induced metabolic dysfunction
following cecal ligation and puncture. Shock Society Meeting, Phoenix, AR, 2003.
3.52) Tissot van Patot, M., Langston, M., Wickham, B., Bendrick-Peart, J., Serkova, N.: Increased hypoxiainducible transcription factor activity correlates with increased anaerobic metabolism in placentas. 13th
International Hypoxia Symposium, Banff, Alberta, Canada, February 19.-22., 2003.
3.53) Christians. U., Serkova, N.J.: Magnetic resonance spectroscopy as a tool to identify mechanisms of
immunosuppressant toxicity. 42nd Annual Meeting of the Society of Toxicology (SOT), Salt Lake City, UT,
March 9.-13., 2003 (invited).
3.54) Fuller, F., Serkova, N., Niemann, C.U., Freise, C.: Influence of donor pretreatment with N-acetylcysteine
on rat kidney graft viability. 81st Annual Meeting of the American Urological Association (AUA), Chicago,
IL, April 26.-May 1., 2003.
3.55) Serkova, N.J., Fuller, F., Freise, C., Niemann, C.U.: Cellular oxidative injury in transplanted rat kidneys
as determined by high-resolution 1H-MRS. 11th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine (ISMRM),Toronto, ON, May 9.-11., 2003.
3.56) Mandell, M., Biancofiore, G., Kindscher, J., Stapefeldt, W., Serkova, N., Plevak, D., Niemann, C.: The
safety of early extubation in liver transplant recipients. 9th Congress of the International Liver
Transplantation Society (ILTS), Barcelona, Spain, June 18.-21., 2003.
3.57) Anderson N and Serkova N: Metabolic and molecular response to imatinib treatment in human leukemia
cells. 26th German Cancer Congress, Berlin, Germany, March 1.-3., 2004.
3.58) Anderson N, Miljus J, Serkova N: Time dependent metabolic effects of imatinib on human leukemia
cells. 95th Annual Meeting of American Association for Cancer Research (AACR), Orlando, FL, March
27.-31., 2004.
3.59) Serkova NJ, Fuller TF, Klawitter J, Freise CE, Hirose R, Niemann CU: Metabolic signatures of mild and
severe ischemia/reperfusion injury in rat kidney transplant model based on 1H-MRS metabonomics.
American Transplant Congress, Boston, MA, May 15.-19., 2004.
3.60) Serkova NJ, Snell L, Lapadat R, Tabakoff B: 1H-MRS based metabolomics on human plasma samples
from alcoholic subjects. RSOA, Vancouver, BC July 9-11, 2004.
3.61) Miljus J, Trump S, Brown J, Leibfritz D, Eckhardt SG, Serkova N: MRS assessment on metabolic
response to a novel EGFR inhibitor ZD1839 in colon cancer cells. ISMRM Cancer Workshop,
Manchester, U.K., October 3-5, 2004.
3.62) Miljus J, Melo JV, Boros L, Anderson N, Talpaz M, Leibfritz D, Eckhardt SG, Serkova N: Metabolic
profile of imatinib resistance in CML cells. 46th American Society of Hematology Annual Meeting,
December 4-7, 2004, San Diego, CA.
3.63) Wischmeyer PE, Singleton KD, Serkova N: Glutamine attenuates multiple pathways of sepsis-induced
injury and improves survival following peritonitis: Role of heat stress protein pathway manipulation.
Society for Critical Care Medicine, Orlando, FL, 2004.
3.64) Serkova NJ, Melo JV, Eckhardt SG: Resistance to Imatinib and glucose metabolism. 96th Annual Meeting
of American Association for Cancer Research (AACR), Anaheim, CA, April 15-20, 2005.
3.65) Miljus J, Melo JV, Anderson N, Boros L, Eckhardt SG, Serkova NJ: MRS ability to predict resistance
development to imatinib mesylate. 13th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine, Miami, FL, May 7-13, 2005.
3.66) Gamito EJ, Serkova N, Jones RH, O’Donnel C, Hedlund T, Crawford ED: Nuclear magnetic resonance
spectroscopy of expressed prostatic secretions: Metabolite citrate and derivatives are potential markers
of prostate cancer. American Urological Association 2005 Annual Meeting, San Antonio, TX, May 21-26,
2005.
3.67) Neville MC, Rudolph M, Serkova N, Anderson S: Molecular anatomy of a profound hormone regulated
metabolic switch: Regulation of glucose and lipid metabolism during the initiation of lactation. 87th Annual
Meeting of the Endocrine Society, San Diego, CA, June 4-7, 2005.
3.68) Peng ZY, Serkova NJ, Kominsky DJ, Brown JL, Wischmeyer PE: Glutamine-mediated attenuation of
cellular metabolic dysfunction and cell death following injury is dependent on heat shock factor-1
expression. Clinical Nutrition Week 2006, Dallas, TX, February 12-15, 2006.
3.69) Serkova NJ, Gamito E, Brown JL, Crawford ED: Validation of citrate and derivatives in expressed
prostatic secretions to predict prostate cancer: High-resolution 1H-NMR study. 97th Annual Meeting of
American Association for Cancer Research (AACR), Washington DC, April 1-5, 2006.
3.70) Serkova NJ, Gamito EJ, Jones RH, O’Donnell C, Crawford ED: Nuclear magnetic resonance
spectroscopy of expressed prostatic secretions: Metabolite citrate and derivates are potential markers of
prostatic cancer. 2006 American Society of Clinical Oncology (ASCO) Annual Meeting, Atlanta, GA, June
2-6, 2006.
3.71) Serkova NJ, Bradshaw EL, Brown M, Gustafson DK, Henthorn TK: Assessment of tumor neovasculature
by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and compartmental modeling in
nude mouse MCF-7 xenografts. 5th Annual Meeting of Molecular Imaging, Big Island, Hawaii, August 29
– September 2, 2006.
3.72) Serkova NJ, Troiani T, Henthorn TK, Eckhardt SG: Novel dual VEGF-R and EGF-R inhibitor decreases
tumor growth and angiogenesis in colon cancer mouse xenografts. 5th Annual Meeting of Molecular
Imaging, Big Island, Hawaii, August 29 – September 2, 2006.
3.73) Larsen BA, Barker AJ, Shandas R, Serkova NJ, Shroyer R, Stoldt CR: Molecular magnetic resonance
imaging of human ovarian carcinoma cells using superparamagnetic immunomicells. 5th Annual Meeting
of Molecular Imaging, Big Island, Hawaii, August 29 – September 2, 2006.
3.74) Serkova NJ: Quantitative Metabolic Markers by High-Resolution Magnetic Resonance Spectroscopy.
232nd National Meeting of the American Chemical Society, San Francisco, CA, September 10-12, 2006.
3.75) Serkova NJ, Troiani T, Bradshaw-Pierce EL, Henthorn TK, Gustafson DL, Eckhardt SG: Inhibition of
tumor growth and angiogenesis by a novel dual EGF-R and VEGF-R inhibitor in mouse xenograft model:
a DCE-MRI study. ISMRM Workshop on Cancer Metabolism and Physiology, Pocono Manor, PA,
October 8-11, 2006.
3.76) Serkova NJ, Gamito EJ, O’Donnell C, Brown JL, Hedlund T, Jones RH, Crawford ED: NMR
spectroscopic validation of metabolic markers of prostatic cancer in human expressed prostatic
secretions. ISMRM Workshop on Cancer Metabolism and Physiology, Pocono Manor, PA, October 8-11,
2006.
3.77) Larsen BA, Haag MA, Serkova NJ, Stoldt CR: Molecular magnetic resonance imaging (MRI) in human
carcinoma cells using superparamagnetic immunomicells. Signaling Transduction Modulators
Symposium, Aurora, CO, December 7-8, 2006.
3.78) Serkova NJ, Kominsky DJ, Brown JL, Miljus J, Boros LG, Eckhardt SG, Melo JV: Abnormalities in
glucose uptake and metabolism in imatinib-resistant Bcr-Abl positive cells. 48th Annual Meeting of the
American Society of Hematology (ASH), Orlando, FL, December 9-12, 2006.
3.79) Tissot van Patot MC, Serkova NJ, Haschke M, Kominsky DJ, Roach R, Sheen P, Griffith V, Roosa J,
Henthorn TK, Honigman B: Elevated circulating succinate and lactate, urinary 15-F21-isoprostanes as
biological markers for hypoxic response in humans acutely exposed to 4,200 m. 15th International
Hypoxia Symposium, Lake Louise, Alberta, Canada, February 27-March 4, 2007.
3.80) Larsen BA, Haag MA, Serkova NJ, Stoldt CR: Effects of surface chemistry and magnetic anisotropy of
superparamagnetic iron oxide nanoparticles for molecular magnetic resonance imaging. 2007 Material
Research Society (MRS) Spring Meeting, San Francisco, CA, April 9-13, 2007.
3.81) Serkova NJ, Takahashi H, Jiang T, Wang X, Brown JL, Kominsky DJ, Moshe L: Consequences of
dietary modification on metabolic profile in SREBP-1c knockout mice. 2007 Experimental Biology Annual
Meeting, Washington, DC, April 28-May 2, 2007.
3.82) Larsen BA, Scaft KM, Haag MA, Serkova NJ, Shroyer KR, Stoldt CR: Molecular magnetic resonance
imaging (MRI) of surface-epithelial-derived protein CA125 in human ovarian carcinoma cells using
superparamagnetic immunomicelles. 15th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine, Berlin, Germany, May 19-25, 2007.
3.83) Kraft S, Lana S, Tuttle H, Ireland L, Brown JL, Serkova NJ: Biopsy-based 1H- and 31P-NMR shows
regional metabolic heterogeneity within canine spontaneous tumors. 15th Scientific Meeting of the
International Society of Magnetic Resonance in Medicine, Berlin, Germany, May 19-25, 2007.
3.84) Zhang L, Chan D, Weisman A, Balamurugan A, Serkova N, Chan L: Short report on NMR imaging of
human islets labeled with nanoparticles. American Transplant Congress, San Francisco, CA, May 5-9,
2007.
3.85) Serkova NJ, Coatney JL, Fuller TF, Wachs ME, Freise C, Mandell MS, Niemann CU: Establishing
metabolic profiling of delayed graft function in kidney recipients. American Transplant Congress, San
Francisco, CA, May 5-9, 2007.
3.86) Serkova NJ, Neville M, Anderson S: Activated AKT1 accelerates mammary tumorigenesis in the MMTVC-ERBB2 transgenic mouse model without activation of ERBB3 and stimulates glycolysis. The 89th
Annual Meeting of the Endocrine Society, Toronto, ON, June 2-5, 2007.
3.87) Tissot van Patot MC, Burton G, Jauniaux E, Serkova N: Oxidative stress and energy metabolism are
similar between healthy and preeclampic placentas at altitude but not between preeclamptic placentas at
low vs. high altitude. The 13th Annual Meeting of the International Federation of Placenta Association
(IFPA), Kingston, ON, August 17-22, 2007.
3.88) Larsen BA, Haag MA, Serkova NJ, Stoldt CR: Micellar multi-SPIO molecular gents: synthesis and
characterization of a novel SPIO aggregate for in vivo ovarian cancer imaging. The Joint Molecular
Imaging Conference, Providence, RI, September 8-11, 2007.
3.89) Bradshaw-Pierce EL, Hasebroock KM, Brown JL, Henthorn TK, Levi M, Serkova NJ: Assessment of
kidney function using DCE-MRI in a mouse nephrectomy model. The Joint Molecular Imaging
Conference, Providence, RI, September 8-11, 2007.
3.90) Kaufman SA, Pitts TM, Serkova NJ, Stephens A, Eckhardt SG, Leong S: In vitro assessment of the IGF1R inhibitor, PQIP, alone and in combination with chemotherapy, against human colorectal cancer cell
lines: antiproliferative, molecular, and metabolic effects. The 19th EORTC-NCI-AACR Symposium on
Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21-25, 2007.
3.91) Glunde K, Bhujwalla ZM, Takagi T, Brown JL, Serkova N: Drug resistance in chronic myeloid leukemia
increases cellular choline kinase and phosphocholine levels. 99th AACR Annual Meeting 2008, San
Diego, CA, April 12-16, 2008.
3.92) Kominsky DJ, Bradshaw-Pierce EL, Brown JL, Raben D, Gustafson DL, Serkova NJ: In vivo and in vitro
metabolic effects of gefitinib and vandetanib in human head and neck cancer models. 99th AACR Annual
Meeting 2008, San Diego, CA, April 12-16, 2008.
3.93) Stringer KA, Pitzer MS, Wilkinson JE, Serkova NJ: Utility of magnetic resonance imaging and
spectroscopy-based metabolomics for the quantification of inflammatory lung injury. The American
Thoracic Society (ATS) 2008, Toronto, ON, May 16-21, 2008.
3.94) Hasebroock KM, McClure WC, Tseng BS, Serkova NJ: Gadolinium-enhanced T1-MRI pinpoints skeletal
muscle pathology in dystrophin deficient mice. The World Molecular Imaging Congress, Nice, France,
September 10-13, 2008.
3.95) Spratlin J, Eckhardt SG, Serkova NJ, Scurr M, Kaye SB, Collins D, George S, Demetri GD, Brock K,
Stephens A, Camidge DR: Analyses of pharmacodynamic (PD) assessments collected during expanded
cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI). 20th
EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Geneva, Switzerland,
October 21-24, 2008.
3.96) Serkova NJ, Spratlin J, Eckhardt SG, Milestone B, Youssoufian H, Fox F, Rowinsky E, Cohen RB: DCEMRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose
escalating study with IMC-1121B. 20th EORTC-NCI-AACR Symposium on “Molecular Targets and
Cancer Therapeutics”, Geneva, Switzerland, October 21-24, 2008.
3.97) Tentler JJ, Pierce ELB, Serkova NJ, Pitts TM, Bray MR, Fletcher GC, Eckhardt SG: ENMD-2076 exerts
antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models.
20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Geneva,
Switzerland, October 21-24, 2008.
3.98) DeRyckere D, Serkova N, Macy M, Gardner L, Jedlicka P, Hasebroock K, Gore L: In vivo imaging of
leukemia in MLL-AF9 transgenic mice using magnetic resonance imaging and spectroscopy. 50th
American Society of Hematology (ASH) Annual Meeting, San Francisco, CA, December 6-9, 2008.
3.99) Ziran NM, Roper E, King KB, Serkova NJ, Hak DJ: The effect of stem cell donor age on in vivo bone
formation. Orthopaedic Research Society (ORS) 55th Annual Meeting, Las Vegas, NV, February 22-25,
2009.
3.100) Bradshaw-Pierce EL, Hasebroock KM, Merz AL, Tentler JJ, Eckhardt SG, Serkova NJ: Quantitative
assessment of treatment response to molecularly targeted agents by DCE-MRI and 18FDG-PET in
Colorectal Cancer Mouse Models. 4th Imaging in Pre-Clinical and Clinical Drug Development Conference,
San Francisco, CA, March 16-18, 2009.
3.101) Serkova NJ, Raina K, Merz AL, Agarwal R: Silibinin feeding alters the metabolic profile in TRAMP
prostatic tumors: a 1H-NMR study. 17th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine, Honolulu, HI, April 18-24, 2009.
3.102) Serkova NJ, Larsen BA, Renner B, Hasebroock KM, Bradshaw-Pierce EL, Holers M, Stoldt C,
Thurman JM: Molecular imaging using targeted nanoparticles for non-invasive detection of renal
inflammation. 17th Scientific Meeting of the International Society of Magnetic Resonance in Medicine,
Honolulu, HI, April 18-24, 2009.
3.103) DeRyckere D, Macy ME, Hasebroock KM, Gardner LA, Jedlicka P, Bradshaw-Pierce EL, Merz AL,
Gore L, Serkova NJ: MRI/ MRS on leukemia development in MLL-AF9 transgenic mice. 17th Scientific
Meeting of the International Society of Magnetic Resonance in Medicine, Honolulu, HI, April 18-24, 2009.
3.104) Bradshaw-Pierce EL, Hasebroock KM, Merz AL, Tentler JJ, Eckhardt SG, Serkova NJ: Quantitative
DCE-MRI and positron emission tomography (PET) for assessment of treatment response in a mouse
xenograft model of colorectal cancer. 17th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine, Honolulu, HI, April 18-24, 2009.
3.105) Raina K, Serkova NJ, Agarwal R: Silibinin feeding alters the metabolic profile in TRAMP prostatic
tumors: 1H-NMRS-based metabolomics study. 100th AACR Annual Meeting 2009, Denver, CO, April 1216, 2009.
3.106) Dang K, Melcher ML, Park Y, Hirose R, Serkova NJ, Niemann CU: Targeted quantitative metabolomics
in rats during the early reperfusion period. ILTS 15th Annual International Congress, New York, NY, July
8-11, 2009.
3.107) Cohen MJ, Serkova NJ, Wiener-Kronish J, Pittet JF, Niemann CU: 1H-NMR based metabolic
signatures in trauma patients: Metabolic profiling beyond lactate and basis deficit. 68th Annual Meeting of
the American Association for the Surgery and Trauma, Pittsburgh, PA, October 1-3, 2009.
3.108) DeRyckere D, Gore L, Gardner LA, Merz AL, Serkova N: Identification of altered metabolic pathways in
a mouse model of acute myeloid leukemia. 21st EORTC-NCI-AACR Symposium on “Molecular Targets
and Cancer Therapeutics”, Boston, MA, October 21-24, 2009.
3.109) Serkova NJ, Hasebroock KM, Bradshaw-Pierce EL, Stoldt C, Thurman JM: Molecular imaging for noninvasive detection of renal inflammation by MRI. 57th Annual Meeting of the Association of University
Anesthesiologists (AUA), Denver, CO, April 8-10, 2010.
3.110) Ramasamy K, Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, Malkinson AM, Agarwal R:
Silibinin selectively inhibits growth and progression of urethane-induced lung tumors in wild-type but not
inducible nitric oxide synthase (-/-) mice: potential usefulness of micro-CT in lung cancer
chemoprevention studies. AACR 101st Annual Meeting, Washington, DC, April 17-21, 2010.
3.111) Raina K, Ravichandran K, Rajamanickam S, Hasebroock KM, Serkova NJ, Agarwal R: Energy
deprivation by inositol hexaphospatase inhibits prostate tumor growth and progression in TRAMP mice.
AACR 101st Annual Meeting, Washington, DC, April 17-21, 2010.
3.112) Raina K, Agarwal C, Serkova NJ, Agarwal R: Molecular mechanism of cell death by silibinin in
colorectal cancer: apoptosis versus autophagy. AACR 101st Annual Meeting, Washington, DC, April 1721, 2010.
3.113) Wu PH, Fay T, Serkova NJ, Beresford TP: Cyclosporine reduces alcohol consumption independent of
sucrose consumption in C57BL mice. 33rd Annual Research Society of Alcoholism (RSA) Scientific
Meeting, San Antonio, TX, June 26-30, 2010.
3.114) Kraft S, Lana S, Ehrhart EJ, Carlsten K, Merz AL, Bucy D, Serkova NJ: Metabolic response to
chemotherapy in multicentric canine lymphoma by biopsy-based nuclear magnetic resonance (NMR)
spectroscopy. World Molecular Imaging Conference, Kyoto, Japan, September 8-11, 2010.
3.115) Serkova NJ and Eckhardt SG: Differential responses to cytotoxic and cytostatic agents by metabolic
and functional imaging end-points. ISMRM Scientific Workshop on Advanced Cancer MRI, Santa Cruz,
CA, September 19-22, 2010.
3.116) Serkova NJ, Bradshaw-Pierce EL, Hasebroock KM, Merz AL, Pitts TM, Eckhardt SG: Imaging endpoints to predict response to IGF1R/IR inhibition in CRC models. AACR Molecular Diagnostics in Cancer
Therapeutic Development: Challenges and New Horizons Conference, Denver, CO, September 27-30,
2010.
3.117) Strand K, Loram LC, Taylor FR, Sloane EM, Rieger J, Maier SF, Serkova NJ, Watkins LR: Adenosine
2A receptor (A2aR) agonists in multiple sclerosis in rats: multi-week resolution of pain or paralysis with
single intrathecal (IT) dosing. Society for Neuroscience Annual Meeting, San Diego, CA, November 1317, 2010.
3.118) Frey L, Lepkin A, Schickedanz A, Hasebroock KM, Serkova NJ: Blood-brain barrier disruption (BBBD)
by T1-weighted MRA as a biomarker for seizure susceptibility after experimental brain injury. 64th Annual
Meeting of the American Epilepsy Society, San Antonio, TX, December 3-7, 2010.
3.119) Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C, McFann K, Thurman JM:
MRI-based detection of tissue fixed complement C3 fragments to monitor disease activity in lupus
nephritis. 19th Scientific Meeting of the International Society of Magnetic Resonance in Medicine,
Montreal, QE, Canada, May 3-8, 2011.
3.120) Fredrickson J, Serkova N, Carano R, Wyatt S, Pirzkall A, Weekes C, Silverman J, Rosen L, de
Crespigny A: Clinical translation of VSI using Ferumozytol: Feasibility in a phase I oncology clinical trial
population. 20th Scientific Meeting of the International Society of Magnetic Resonance in Medicine,
Melbourne, Australia, May 5-11, 2012.
3.121) Bluth JS, Loram LC, Brown MS, Hasebroock KM, Miller DE, Watkins LR, Serkova NJ: MRI detection of
spinal lesions in a rat MS model. 20th Scientific Meeting of the International Society of Magnetic
Resonance in Medicine, Melbourne, Australia, May 5-11, 2012.
3.122) Serkova NJ, Bradshaw-Pierce EL, Rowe MD, Hasebroock KM, Merz AL, Boyes SG: Targeted
gadolinium MOF nanoparticles as a positive contrast for MR imaging on EGFR expression. 20th Scientific
Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Melbourne, Australia,
May 5-11, 2012.
3.123) Yang T, Serkova NJ, Lim L, Maze M, Niemann CU: Xenon and isoflurane preconditioning elevate the
mitochondrial function related gene expression in the liver in rat. American Society of Anesthesiology
(ASA) Annual Meeting, Washington, D.C., October 13-17, 2012.
3.124) Serkova NJ, Huber KM, Renner B, Pickering MC, Thurman JM: Non-invasive detection of
glomerulonephritis by MRI-based molecular imaging. The American Nephrology Society (ASN) Kidney
Week 2012 Annual Meeting, San Diego, CA, November 1-4, 2012.
3.125) Stukova M, Golovko D, Huber K, Frederick B, Thurman J, Serkova NJ: Time-course for macrophage
detection in vivo by ferumoxytol-enhanced T2-MRI. The 2013 World Molecular Imaging Conference
(WMIC), Savannah, GA, September 18-21, 2013.
3.126) Schlaepfer I, Eckel R, Serkova NJ, Glode M, Cramer S: Enhancement of 18-FDG-PET in prostate
cancer xenografts using lipid metabolic inhibitors. The 2013 World Molecular Imaging Conference
(WMIC), Savannah, GA, September 18-21, 2013.
3.127) Serkova NJ, Huber KM, Hicks D, Smith-Jones P, Spillman MA: 18F-Estrogen PET in orthotopic mouse
xenograft models for ovarian cancer. American Association for Cancer Research (AACR) Ovarian
Cancer Workshop, Miami, FL, September 18-20, 2013.
3.128) Serkova NJ, Hammond BG, Poth J, Huber KM, Stukova M, Golovko D: Magnetic resonance imaging
(MRI) on macrophage-based inflammation in a mouse renal ischemia-reperfusion model using superparamagnetic iron oxide (SPIO) nanoparticles. American Society of Anesthesiology (ASA) Annual
Meeting, San Francisco, CA, October 12-16, 2013.
3.129) Henry CJ, Marusyk A, Zaberezhnyy V, Casas-Selves M, Serkova NJ, DeGregori J: Inflamm-aging
reduces B-progenitor function leading to increased selection for oncogenically-initiated B-cells.
Inflammation, Infection and Cancer (X1) Keystone Meeting, Whistler, British Columbia, Canada, March
9-14, 2014.
3.130) Deep G, Ramteke AM, Nambiar DK, Jain AK, Serkova NJ, Agarwal C, Agarwal R: Silibinin inhibits
hypoxia-induced proliferation, angiogenesis and lipogenesis in prostate cancer cells both in vitro and in
vivo. American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 5-9,
2014.
3.131) Schlaepfer IR, Pac CT, Serkova NJ, Deep G, Agarwal R, Cramer SD, Eckel RH, Glode LM: Lipid
metabolism inhibitors enhance glycolysis and FDG uptake by PET in prostate cancer tumors. American
Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 5-9, 2014.
3.132) Lee JY, Wilson LA, Choi JM, Huber KM, Merz AL, Weekes CD, Serkova NJ: A multimodality imaging
end-point study of everolimus and ganetespib in treatment of pancreatic cancer: a pre-clinical
PET/MRI/MRS study. American Association for Cancer Research (AACR) Annual Meeting, San Diego,
CA, April 5-9, 2014.
3.133) Borgen LK, Murphy CM, Johnson EL, Sinha N, Serkova NJ, Drew KL: 1H-NMR metabolomics
biomarkers of poor outcome after hemorrhagic shock are absent in hibernators. Experimental Biology
Conference, San Diego, CA, April 26-30, 2014.
3.134) Lee JY, Wilson LA, Choi JM, Huber KM, Merz AL, Kechris KJ, Weekes CD, Serkova NJ: Multimodality
imaging end-points on mTOR and HSP inhibition in pancreatic cancer: A pre-clinical PET/MRI/MRS
study. 22nd Scientific Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM),
Milan, Italy, May 9-16, 2014.
3.135) Stringer KA, Jones AE, Puskarich MA, Karnovsky A, Serkova NJ: Increased lipid levels by 1H-NMR
associated with apoptosis differentiate acute respiratory distress syndrome (ASRD) from sepsis.
American Thoracic Society (ATS) Conference, San Diego, CA, May 16-21, 2014.
3.136) Little T, Ryan AJ, Steffens FE, Serkova NJ, Meyer D: Associative metabolic changes in HIV-1 infected
patients, influence of ART and quantitative lipid analyses using 1H-NMR. Kern Lipid Conference 2014,
Vail, CO, August 4-7, 2014.
Invited Lectures:
1996
“MRS application to the evaluation of volume regulation and metabolic alterations in primary astrocytes”,
Radiology Department, Johns Hopkins University, Baltimore, MD.
1997
“Possibilities of NMR spectroscopy in biopharmaceutical research”, Department of Biopharmaceutical
Sciences, University of California, San Francisco, CA.
1998
“Neurotoxic screening of immunosuppressive drugs by 31P-MRS on perfused rat brain slices ex vivo”,
Department of Neurosurgery, Stanford University, Stanford, CA.
“NMR for drug toxicity in transplantation medicine”, Department of Anesthesiology, University of Pittsburg,
Pittsburg, PA.
1999
“MRS on perfused organs”, Department of Radiology, DVA Medical Center, San Francisco, CA
“Does impairment of energy metabolism result in cyclosporine
Biopharmaceutical Sciences, University of California, San Francisco, CA.
neurotoxicity?”,
Department
of
“Cyclosporine in the brain: from neurotoxicity to neuroprotection”, Department of Chemistry/Biology, University
of Bremen, Germany.
“Role of calcineurin and immunophilins in neurotoxicity of immunosuppressants”, Department of Cardiothoracic
Surgery, Stanford University, Stanford, CA.
2000
“Evaluation of the effect of cyclosporine, sirolimus, and RAD alone and in combination on cell metabolism”,
Preclinical Safety Department, Novartis Pharmaceuticals, Basel, Switzerland.
“The importance of evaluating mechanisms of toxicity: RAD and sirolimus have opposite effects on cell
metabolism”, 18th International Congress of the Transplantation Society, Rome, Italy.
2001
“MRS (magnetic resonance spectroscopy) as preclinical test for the efficacy and metabolic toxicity of novel
drugs”, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO.
“MRS/MRI in biomedical research”, Bayer AG, Wuppertal, Germany.
2002
“Kidney metabolic toxicity of novel immunosuppressants: everolimus versus sirolimus in combination with
cyclosporine”, Preclinical Safety Department, Novartis Pharmaceuticals, Basel, Switzerland.
“MRS in islet transplantation”, Departments of Anesthesia and Surgery, University of California, San Francisco,
CA.
“Biomedical Magnetic Resonance (MRI/MRS) Center at UCHSC: from cells to the human”, Animal Cancer
Center, Colorado State University, Fort Collins, CO.
2003
“Magnetic resonance spectroscopy (MRS) for metabolic evaluations: from the cell to the human”, Department
of Pharmacology, University of Colorado Health Sciences Center, Denver, CO.
“Magnetic resonance spectroscopy: Cell metabolism in hypoxia and reperfusion”, Colorado Center for Altitude
Medicine and Physiology (CCAMP) Seminar, University of Colorado Health Sciences Center, Denver, CO.
“MRI/MRS in diagnosis and treatment of prostate cancer”, 13th International Prostate Cancer Update, Vail, CO.
“Magnetic resonance spectroscopy as a tool to identify mechanisms of immunosuppressant toxicity”, 42nd
Annual Meeting of the Society of Toxiclology (SOT), Salt Lake City, UT.
“MRS-based metabonomics to evaluate metabolic toxicity of novel immunosuppressants”, Toxicology and
Inflammatory Diseases Unit, Roche Bioscience, Palo Alto, CA.
“Metabonomics: A new approach in pharmacodynamics and toxicodynamics”, Sanofi-Synthelabo Research
Inc., Malvern, PA.
“Magnetic resonance spectroscopy (MRS) for metabolic prediction of anticancer drug resistance”, 8th World
Congress on Advances in Oncology, Crete, Greece.
2004
“Cancer Metabolism and Its Changes Upon TKI Treatment: NMR from the Bench top to The Patient Bed”,
Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD.
“Quantitative MRS based Metabolomics in Drug Discovery: Pharmacodynamics and Toxicodynamics”, SMASH
2004 Conference Program, Breckenridge, CO.
“Magnetic Resonance (MRI/MRS) in Translational Research in Cancer and Anti-Cancer Treatment”, Colorado
Cancer Center Symposium Series, Denver, CO.
“Quantitative NMR based Metabolomics: From Method Validation to Biomedical Application”, 2004 Bruker User
Meeting, San Jose, CA.
“Metabolic Signature of Small Molecule Tyrosine Kinase Inhibitors by MRS – from Efficacy to Resistance
Development”, Cambridge Healthtech Institute Conference, Miami, FL.
2005
“MRS Based Metabolomics as a PD Tool for Novel TKIs”, The Third Annual Opinion Leader Consortium on
Novel and Targeted Therapies for Head and Neck Cancer, Astra Zeneca, Cancun, Mexico.
“From Proteomics to Metabonomics”, Continuing Medical Education Program Controversies in Transplantation,
Breckenridge, CO.
Roundtable: “NMR-based Metabonomics as a Potential Clinical Tool for Monitoring Efficacy and Toxicity of
Drug Therapy”, 9th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Louisville,
KE.
“Identification of Biomarkers for the Toxicodynamics Monitoring of Immunosuppressants Using an MRS-based
Quantitative Metabonomics Approach”, 9th International Congress of Therapeutic Drug Monitoring and Clinical
Toxicology, Louisville, KE.
“Blood Metabolic Profiling in Transplantation by Quantitative 1H-NMR Spectroscopy”, Metabolic Profiling in
Drug Discovery, London, UK
“Metabolomics: Principles and Practice”, UCDHSC Research Symposium on Systems Biology in Biomedical
Research, Denver, CO
“Quantitative 1H-NMR Metabolomics to Monitor Graft Outcome After Transplantation”, Cambridge Healthtech
Institute Conference on Metabolic Profiling, Miami, FL.
2006
“Assessment of Efficacy of Novel Targeted Drugs by MRI/MRS”, University of Colorado Cancer Center,
Developmental Therapeutics Program Retreat, Aurora, CO.
“MR Imaging for In Vivo Cancer Models and Novel Therapeutics”, 4th Annual Opinion Leader Consortium on
Novel and Targeted Therapies for Head and Neck Cancer, Key Biscayne, FL.
“Blood analysis for Cancer Prediction”, Interview for Colorado 7News Channel
“Quantitative Blood Metabolomics in Organ Transplantation”, Advances in Functional Genomics, San
Francisco, CA.
“Quantitative Metabolic Markers by High-Resolution Magnetic Resonance Spectroscopy”, American Chemical
Society, San Francisco, CA.
“Biomedical MRI/ MRS: from Cell Metabolism to Animal Physiology”, Department of Medicine Monthly
Research Conference, UCHSC, Denver, CO.
“Magnetic Resonance in Biomedicine: From Metabolomics to Physiology”, Key Note Speaker for Women’s
Health Investigator Network Fall Forum 2006, Denver, CO.
“Metabolic Consequences of Therapeutic Responsiveness and Resistance Development to Novel Targeted
Therapies”, 5th International Congress on Cancer Metabolism, Louisville, KY.
“Metabolic and Physiological Response to EGFR Inhibition by Novel Small Molecule Tyrosine Kinase
Inhibitors”, UCHSC Department of Pharmacology Retreat, Copper Mountain, CO.
“Metabolic Markers in Translational Transplantation”, UCHSC Department of Anesthesiology Research
Seminar, Denver, CO.
“Magnetic Resonance – from Cell Biochemistry to Animal Physiology”, UCHSC Biomolecular Structure
Program Grand Rounds, Aurora, CO.
“Magnetic Resonance to Assess Therapeutic Response”, Signaling Transduction Modulators Symposium,
Aurora, CO.
“1H-NMR Based Metabolomics: Translational Applications to Transplantation”, 7th Annual Cambridge
Healthtech Institute’s Meeting on Metabolic Markers, Orlando, FL.
2007
“Magnetic Resonance in Medicine: From Metabolomics to Molecular Imaging”, UCHSC Department of
Endocrinology, Aurora, CO.
“Small Animal Imaging at UCHSC: Optical, MRI, microPET/CT”, Department of Immunology Grand Rounds,
the National Jewish Center, Denver, CO.
“NMR Spectroscopy and Neurological Outcome in Children with Congenital Heart Disease”, Department of
Surgery and Anesthesiology Grand Rounds, the Children’s Hospital, Denver, CO.
“NMR-Based Metabolomics of Immunosuppressant Toxicity After Organ Transplantation”, Cambridge
Healthtech Institute Biomarker Discovery Summit, Philadelphia, PA.
“Application of Imaging Modalities in Pre-Clinical Research”, UCHSC Department of Obstetrics and
Gynecology Grand Rounds, Aurora, CO.
2008
“Small Animal Imaging in Colorado”, Grand Rounds, Immunology Department, National Jewish Medical
Center, CO.
“Translational Imaging Endpoints in Oncology: From Pre-Clinical Imaging to IRAT”, Educational Rounds,
Radiology Department, UCHSC, Aurora, CO.
“NMR-Based Metabolomics: Translational Application in Cancer and Anti-Cancer Treatment”, Cambridge
Healthtech Institute, Biomarker Discovery Summit, Philadelphia, PA.
“Pre-Clinical and Clinical DCE-MRI on Novel VEGFR-Targeting Drugs”, Department of Radiology, Penn
University, Philadelphia, PA.
“Novel Imaging Approaches in Pre-clinical and Clinical Setting”, The Rocky Mountain Nuclear Medicine
Technologist Association, Englewood, CO.
“Imaging in Vivo Omics – The End of the Cold War in Translational Medicine”, American Society of
Anesthesiology, Orlando, FL.
2009
“Establishing Metabolic Profiles of Delayed Graft Function in Blood of Kidney Recipients”, Frontier in Renal
Transplantation, Division of Transplant Surgery, Denver, CO.
“Brain Imaging: Anatomical, Metabolic and Functional Imaging Modalities”, Colorado Intellectual and
Developmental Disabilities Research Center (IDDRC) Seminar Series, Denver, CO.
“Brain Metabolomics”, Colorado Intellectual and Developmental Disabilities Research Center (IDDRC) Seminar
Series.
“Imaging End-Points in Oncology”, Biomarkers in Clinical Trials conference, SMi Group, London, UK.
“Intracellular Pathways of Glucose Metabolism Determine Imatinib Resistance in Leukemia: Potential
Applications for Drug Resistance Testing in Circulating Tumor Cells”, (together with Dr. Laszlo G. Boros,
UCLA/ SIDMAP) NIH Meeting on Circulating Tumor Cells/ Emerging Technologies, Bethesda, MD.
“Imaging Update in Colorado: Animal Imaging and the New C-TRIC”, Department of Anesthesiology Research
Seminar Series, School of Medicine, University of Colorado at Denver, Aurora, CO.
“Functional Imaging to Assess Responsiveness to IGF-1R Inhibition in CRC Models”, Developmental
Therapeutics Program Retreat, University of Colorado Cancer Center, Aurora, CO.
2010
“Anatomical and Functional Imaging in Oncology”, Hormones and Related Malignancies Seminar Series,
School of Medicine, University of Colorado at Denver, Aurora, CO.
“Functional and Molecular Imaging on Animal Models of Cancer”, Colorado State University, Veterinarian
Teaching Hospital, Fort Collins, CO.
“Functional Imaging for IGF-1R Responsiveness in Colorectal Cancer”, University of Colorado Cancer Center
Symposium, UCD, Aurora, CO.
“Functional Imaging in Animal Cancer Models”, Department of Radiology, Colorado Translational Research
Imaging Center (C-TRIC), UCD, Aurora, CO.
2011
“Oncologic Imaging Utilizing 4.7T MRI”, Section for Magnetic Resonance Technologists (SMRT) of the
International Society for Magnetic Resonance in Medicine (ISMRM), 2011 Regional Educational Seminars,
Broomfield, CO.
“Clinical Application of Metabolomics in Cancer”, (co-authored with Gail S. Eckhardt, MD, Plenary Session on
Advance Technologies, American Association for Cancer Research (AACR) 2011 Annual Meeting, Orlando,
FL.
“Next Generation Imaging for Cancer Detection, Staging and Treatment Response”, CCTSI Clinical
Investigator Program Retreat, Aurora, CO.
“Multimodality Imaging of Mice”, Educational Courses at the 2011 Annual Meeting of the ISMRM, Montreal,
Quebec, Canada.
“Physico Chemical Principles of Metal Based Paramagnetic/ Iron Contrast”, Educational Courses at the 2011
Annual Meeting of the ISMRM, Montreal, Quebec, Canada.
“New Oncologic Imaging for the Assessment of Therapy Response”, Bio-Imaging Meeting at the National
Institute of Standard and Time (NIST), Boulder, CO and Washington, DC.
“Current Pre-Clinical Resources at the AMC” VisualSonic Imaging Symposium in Colorado, Aurora, CO.
“1H-NMR Based Metabolomics: Application in Translational and Clinical Medicine” Grand Rounds for the
Department of Computational Medicine and Bioinformatics, Medical School, University of Michigan, Ann Arbor,
MI.
2012
“Imaging genes and proteins non-invasively: Molecular imaging in living animals” Structural Biology and
Biochemistry Graduate Program, Anschutz Medical Center, University of Colorado Denver, Aurora, CO.
“Oncologic Imaging Utilizing 4.7T MRI”, Section for Magnetic Resonance Technologists (SMRT) of the
International Society for Magnetic Resonance in Medicine (ISMRM), 2012 Regional Educational Seminars,
Loveland, CO.
2013
“MRI on Imaging Inflammation Using Targeted and Untargeted Iron Oxide Nanoparticles” Physics Grand
Rounds, University of Colorado, Colorado Springs, CO.
“Animal Imaging and Advances in Brain Imaging” IDDRC Seminar, University of Colorado, Anschutz Medical
Center, Aurora, CO.
“Contrast-Enhanced T2-MRI with Iron Oxide Nanoparticles to Image Tumor Associated Macrophages” Cancer
Center Symposium, Comprehensive Cancer Center, Tampa, FL.
2014
“Imaging Inflammation in Cancer: Pre-Clinical MRI Using Iron Oxide Nanoparticles” Cancer Center
Symposium, University of Colorado Cancer Center, Aurora, CO.
“Animal Oncologic Imaging” Molecular Oncology Retreat, University of Colorado Boulder, Boulder, CO.
“Imaging Inflammation Using Iron Oxide Enhanced MRI” Anesthesiology Grand Rounds, University of
Colorado, Anschutz Medical Center, Aurora, CO.
“Imaging of Cancer Inflammation: The Future of MRI and PET” Endocrinology Grand Rounds, University of
Colorado, Anschutz Medical Center, Aurora, CO.
“Cancer Physiology” 22nd Scientific Meeting of the International Society of Magnetic Resonance in Medicine
(ISMRM), Milan, Italy.
“Imaging of Cancer Treatment Response” Keynote Speaker